<html lang="en" class="pb-page js" data-request-id="94d695b1f5e6f1ff-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d695b1f5e6f1ff-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/KiH4qUKVk_oV4Bki6F8ElBncnCy2IWogje6s1K1jn0p-lyYtL2d7I9M2mWf-yA60glAQotS1pthMfMRFmDh9sw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d695b1f5e6f1ff-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.3136360571880872"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Cardiology|Pulmonary/Critical Care|Infectious Disease">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Coronavirus|Anticoagulation/Thromboembolism (Cardiology)"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2105911","title":"Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19","category":"Research","type":"Original Article","topics":"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Coronavirus|Anticoagulation/Thromboembolism (Cardiology)","specialties":"Cardiology|Pulmonary/Critical Care|Infectious Disease","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-08-26T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Cardiology|Pulmonary/Critical Care|Infectious Disease\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Coronavirus|Anticoagulation/Thromboembolism (Cardiology)\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2105911","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Therapeutic Anticoagulation in Hospitalized Patients with Covid-19","doi":"10.1056/NEJMdo006147","issueDate":"2021-08-26T00:00Z","age":"6Months-1990","isFree":"n","topics":"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Coronavirus|Anticoagulation/Thromboembolism (Cardiology)|Critical Care","viewType":"Full","specialties":"Cardiology|Pulmonary/Critical Care|Infectious Disease"},{"type":"Research Summary","title":"Therapeutic Anticoagulation with Heparin in Non-Critically Ill Patients with Covid-19 Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19","doi":"10.1056/NEJMdo006148","issueDate":"2021-08-26T00:00Z","age":"6Months-1990","isFree":"n","topics":"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Coronavirus|Anticoagulation/Thromboembolism (Cardiology)","viewType":"Full","specialties":"Cardiology|Pulmonary/Critical Care|Infectious Disease"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d695b1f5e6f1ff-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19"><meta name="dc.Creator" content="The ATTACC, ACTIV-4a, and REMAP-CAP Investigators"><meta name="dc.Description" content="Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may ..."><meta name="Description" content="Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may ..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-08-26"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2105911"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202108263850906"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2111151"><meta name="dc.Relation" content="10.1056/NEJMoa2103417"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2105911">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2105911">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2105911">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 | NEJM">
        <meta property="og:title" content="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2105911">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/d477dd93-5bc5-43ef-aef8-5832aad30af4/nejmoa2105911_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/d477dd93-5bc5-43ef-aef8-5832aad30af4/nejmoa2105911_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Thrombosis and inflammation may contribute to the risk of death and complications
among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose
anticoagulation may ...">
        <meta name="twitter:description" content="Thrombosis and inflammation may contribute to the risk of death and complications
among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose
anticoagulation may ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2105911">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105911">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2105911;issue:issue:doi\:10.1056/nejm_2021.385.issue-9;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2105911" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2105911" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2105911" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2105911" class="inputDoi"><input type="hidden" value="The ATTACC, ACTIV-4a, and REMAP-CAP Investigators" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:790-802" class="inputCitation"><input type="hidden" value="08-04-2021" class="inputEPubDate"><input type="hidden" value="August 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d695b1f5e6f1ff-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Author</span>: <span role="list"><span property="author" typeof="Person" role="listitem">The ATTACC, ACTIV-4a, and REMAP-CAP Investigators<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">August 4, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">790</span>-<span property="pageEnd">802</span></div><div class="doi">DOI: 10.1056/NEJMoa2105911</div><div class="core-enumeration"><a href="/toc/nejm/385/9"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">9</span></span></a></div><div><a href="#tab-information">Copyright Â© 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D9%26contentID%3D10.1056%252FNEJMoa2105911%26title%3DTherapeutic%2BAnticoagulation%2Bwith%2BHeparin%2Bin%2BNoncritically%2BIll%2BPatients%2Bwith%2BCovid-19%26publicationDate%3D08%252F26%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2105911" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3D%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D9%26contentID%3D10.1056%252FNEJMoa2105911%26title%3DTherapeutic%2BAnticoagulation%2Bwith%2BHeparin%2Bin%2BNoncritically%2BIll%2BPatients%2Bwith%2BCovid-19%26publicationDate%3D08%252F26%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/d4c433da-c161-4421-ad33-b56eed08711a/nejmoa2105911.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2105911.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105911" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2105911" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2105911.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned patients who were hospitalized with Covid-19 and who were not critically ill (which was defined as an absence of critical careâlevel organ support at enrollment) to receive pragmatically defined regimens of either therapeutic-dose anticoagulation with heparin or usual-care pharmacologic thromboprophylaxis. The primary outcome was organ supportâfree days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of â1) and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. This outcome was evaluated with the use of a Bayesian statistical model for all patients and according to the baseline <span data-style="small-caps">d</span>-dimer level.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f0.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/d477dd93-5bc5-43ef-aef8-5832aad30af4/assets/images/large/nejmoa2105911_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">The trial was stopped when prespecified criteria for the superiority of therapeutic-dose anticoagulation were met. Among 2219 patients in the final analysis, the probability that therapeutic-dose anticoagulation increased organ supportâfree days as compared with usual-care thromboprophylaxis was 98.6% (adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58). The adjusted absolute between-group difference in survival until hospital discharge without organ support favoring therapeutic-dose anticoagulation was 4.0 percentage points (95% credible interval, 0.5 to 7.2). The final probability of the superiority of therapeutic-dose anticoagulation over usual-care thromboprophylaxis was 97.3% in the high <span data-style="small-caps">d</span>-dimer cohort, 92.9% in the low <span data-style="small-caps">d</span>-dimer cohort, and 97.3% in the unknown <span data-style="small-caps">d</span>-dimer cohort. Major bleeding occurred in 1.9% of the patients receiving therapeutic-dose anticoagulation and in 0.9% of those receiving thromboprophylaxis.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis. (ATTACC, ACTIV-4a, and REMAP-CAP ClinicalTrials.gov numbers, <a href="http://clinicaltrials.gov/show/NCT04372589" target="_blank">NCT04372589</a>, <a href="http://clinicaltrials.gov/show/NCT04505774" target="_blank">NCT04505774</a>, <a href="http://clinicaltrials.gov/show/NCT04359277" target="_blank">NCT04359277</a>, and <a href="http://clinicaltrials.gov/show/NCT02735707" target="_blank">NCT02735707</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006147/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/3b19f064-77e9-4dd0-80f4-e4b681e2f904/media/NEJMdo006147_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006147/full/" class="ng-do-media_item-title-link">Therapeutic Anticoagulation in Hospitalized Patients with Covid-19</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 51s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">In some patients, the clinical course of coronavirus disease 2019 (Covid-19) is characterized by an initial period of mild-to-moderate symptoms, followed by progressive respiratory failure leading to cardiovascular or respiratory organ support or death.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> However, the majority of patients who are hospitalized with Covid-19 are moderately ill and do not initially require organ support in an intensive care unit (ICU).<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5" id="body-ref-r5" href-manipulated="true">3-5</a></sup> Limited therapies are available to prevent progression to organ failure and death among moderately ill patients.</div><div role="paragraph">Patients who are hospitalized with Covid-19 frequently have macrovascular and microvascular thrombosis and inflammation, which are associated with a poor clinical outcome.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> Given the antithrombotic, antiinflammatory, and possibly antiviral properties of heparins,<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10" id="body-ref-r10-1" href-manipulated="true">8-10</a></sup> it has been hypothesized that anticoagulation with heparin administered at doses higher than conventionally used for venous thromboprophylaxis may improve outcomes.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> Furthermore, an elevated <span data-style="small-caps">d</span>-dimer level has been associated with vascular thrombosis and a poor clinical outcome.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r12" id="body-ref-r12" href-manipulated="true">6,12</a></sup> Thus, some practitioners have advocated an evaluation of <span data-style="small-caps">d</span>-dimer levels to guide anticoagulant administration. In the absence of data from randomized trials, clinical-guideline recommendations<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup> and practice<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> vary widely.</div><div role="paragraph">We conducted an international, adaptive, multiplatform, randomized, controlled trial to determine whether an initial strategy of therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin improves in-hospital survival and reduces the duration of ICU-level cardiovascular or respiratory organ support among hospitalized patients with Covid-19 who are not critically ill.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">To accelerate evidence generation, we integrated three platforms evaluating therapeutic-dose anticoagulation with heparin in patients hospitalized with Covid-19 into a single multiplatform, randomized, controlled trial. The participating platforms were Antithrombotic Therapy to Ameliorate Complications of Covid-19 (ATTACC),<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a), and Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP).<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> During the trial period, patients with moderate Covid-19 disease were enrolled at 121 sites in 9 countries (the United States, Canada, the United Kingdom, Brazil, Mexico, Nepal, Australia, the Netherlands, and Spain). We prospectively aligned eligibility criteria, interventions, outcome measures, and data collection. (Comparisons of the three platforms are provided in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org.) Independent data and safety monitoring boards oversaw the platforms on the basis of a collaborative cross-platform interaction plan. The trial <a href="#ap1">protocols</a> and unified statistical analysis plan are also available at NEJM.org.</div><div role="paragraph">The trial was approved by the relevant ethics committees and conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation. All the patients or their surrogates provided written or oral informed consent, in accordance with regional regulations. The trial was supported by multiple international funding organizations, which had no role in the design, analysis, or reporting of trial results, apart from the ACTIV-4a protocol, which received input on design from professional staff members at the National Institutes of Health and from peer reviewers. The members of the writing committees vouch for the accuracy and completeness of the data and for the fidelity of the trials to the protocols.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">The multiplatform trial enrolled patients who were hospitalized with Covid-19. The investigators hypothesized that the benefits and risks of therapeutic-dose anticoagulation would vary according to disease severity. As such, the design prospectively stratified patients according to whether they had severe disease (ICU-level care or critically ill) or moderate disease (hospitalized but noncritically ill) at enrollment. This report describes the results of the analyses involving patients with moderate Covid-19; the results of analyses involving patients with severe Covid-19 are reported separately.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-1" href-manipulated="true" aria-label="Reference 17">17</a></sup></div><div role="paragraph">Moderate disease severity was defined as hospitalization for Covid-19 without the need for ICU-level care. ICU-level care was defined as the use of respiratory or cardiovascular organ support (oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes) in an ICU. In ACTIV-4a, in which investigators found that ICU-level care was challenging to define during the pandemic, receipt of organ support, regardless of hospital setting, was used to define ICU-level care. Patients who were admitted to an ICU but without receiving qualifying organ support were considered to be moderately ill.</div><div role="paragraph">Patients with moderate disease were further stratified according to their baseline <span data-style="small-caps">d</span>-dimer level as follows: a high <span data-style="small-caps">d</span>-dimer level (â¥2 times the upper limit of the normal range [ULN], according to local laboratory criteria), a low <span data-style="small-caps">d</span>-dimer level (&lt;2 times the ULN), and an unknown <span data-style="small-caps">d</span>-dimer level. Patients were ineligible for enrollment in the ATTACC and ACTIV-4a platforms if 72 hours had elapsed since hospital admission for Covid-19 or since in-hospital confirmation of the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); in the REMAP-CAP platform, patients were ineligible if 14 days had elapsed since admission. Patients were also excluded if hospital discharge was expected within 72 hours or if they had a clinical indication for therapeutic anticoagulation, a high risk of bleeding, receipt of dual antiplatelet therapy, or a known heparin allergy, including heparin-induced thrombocytopenia (HIT). (Details regarding eligibility are provided in the <a href="#ap2">Supplementary Appendix</a>.)</div></section><section id="sec-1-3"><h3>Randomization</h3><div role="paragraph">We used central Internet-based systems to randomly assign patients to receive either therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin or usual-care pharmacologic thromboprophylaxis in an open-label fashion. Therapeutic-dose anticoagulation was administered according to local protocols for the treatment of acute venous thromboembolism for up to 14 days or until recovery; the latter was defined as hospital discharge or a discontinuation of supplemental oxygen for at least 24 hours. Thromboprophylaxis was provided at a dose and duration determined by the treating clinician according to local practice. The anticoagulation and thromboprophylaxis regimens are detailed in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">Treatments were initially randomly assigned in a 1:1 ratio. The ATTACC and REMAP-CAP designs specified the possibility of response-adaptive randomization, in which group-assignment ratios could be modified in a blinded fashion during the trial on the basis of response-adaptive interim analyses to favor the assignment of patients to the treatment group showing greater benefit. (Details regarding the methods used in adaptive randomization are provided in the <a href="#ap2">Supplementary Appendix</a>.) A subset of patients in the REMAP-CAP platform underwent randomization to other platform domains, including an antiplatelet domain.</div></section><section id="sec-1-4"><h3>Outcome Measures</h3><div role="paragraph">The primary outcome was organ supportâfree days, evaluated on an ordinal scale that combined in-hospital death and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. Patients who were discharged from the hospital before day 21 were assumed to be alive and free of organ support through day 21. Any death during the index hospitalization through 90 days was assigned the worst score on the outcome scale (â1). This end point reflects both the use of ICU-level interventions and survival, with higher values indicating better outcomes.</div><div role="paragraph">Secondary efficacy outcomes included survival until hospital discharge, survival without receipt of organ support, survival without receipt of invasive mechanical ventilation, survival without mechanical respiratory support, length of hospital stay, a major thrombotic event or death (a composite of myocardial infarction, pulmonary embolism, ischemic stroke, systemic arterial embolism, or in-hospital death), and any thrombotic event including deep venous thrombosis. Secondary safety outcomes that were assessed during the treatment period were major bleeding (as defined according to the criteria of the International Society on Thrombosis and Haemostasis<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup>) and laboratory-confirmed HIT. All reported bleeding and thrombotic events were adjudicated in a blinded fashion by clinical end-points committees using consensus definitions (as described in the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We performed the primary analysis using a Bayesian cumulative logistic model that calculated the posterior probability distribution for the proportional odds ratio for therapeutic-dose anticoagulation as compared with usual-care thromboprophylaxis with respect to organ supportâfree days in patients with confirmed SARS-CoV-2 infection. Although REMAP-CAP enrolled patients with suspected or confirmed Covid-19, only patients who had infection that was confirmed by laboratory testing were included in the main analyses. The primary model incorporated weakly informative Dirichlet prior distributions for the number of days without organ support and was adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period (in 2-week intervals). The model was fitted with the use of a Markov chain Monte Carlo algorithm with 100,000 samples from the joint posterior distribution, which allowed for calculation of the posterior distributions for the proportional odds ratios, including medians and 95% credible intervals, and the posterior probabilities of superiority and futility for the comparison between therapeutic-dose anticoagulation and usual-care thromboprophylaxis.</div><div role="paragraph">The primary model estimated treatment effects for each of the groups according to disease severity (severe or moderate, with the latter stratified according to the baseline <span data-style="small-caps">d</span>-dimer level) by means of a Bayesian hierarchical method. The treatment effects of anticoagulation for the groups were nested in a hierarchical prior distribution centered on an overall intervention effect estimated with a neutral prior distribution, but distinct group-specific effects were estimated. With regard to the primary outcome of organ supportâfree days, when consistent effects were observed for the groups, the posterior distribution for each intervention group effect was shrunk toward the overall estimate (dynamic borrowing).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-1" href-manipulated="true" aria-label="Reference 19">19</a></sup> Secondary end points were modeled without dynamic borrowing. The stopping criteria for treatment superiority (&gt;99% probability of an odds ratio of &gt;1.0) and futility (&lt;5% probability of an odds ratio of &gt;1.2) were evaluated monthly by an independent statistical analysis committee and could be reached separately in the low and high <span data-style="small-caps">d</span>-dimer subgroups at each adaptive analysis; no stopping criteria were defined for the cohort with an unknown <span data-style="small-caps">d</span>-dimer level. Several sensitivity analyses of the primary model are also reported. (Details regarding the sensitivity analyses are provided in the <a href="#ap2">Supplementary Appendix</a>.) In addition, we present analyses involving patients with moderate disease that assume a single treatment effect regardless of the <span data-style="small-caps">d</span>-dimer level.</div><div role="paragraph">Subgroup analyses assessed the treatment effect according to age, sex, baseline respiratory support, and dose of thromboprophylactic drugs. Protocol adherence was defined according to the anticoagulant dose equivalent administered within the first 24 to 48 hours after randomization. The receipt of doses that were categorized as therapeutic or subtherapeutic heparin qualified as adherence in the therapeutic-dose anticoagulation group, and the receipt of low-dose or intermediate-dose thromboprophylactic drugs qualified as adherence in the usual-care thromboprophylaxis group.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Characteristics of the Patients</h3><div role="paragraph">The first patients underwent randomization on April 21, 2020. On January 22, 2021, enrollment was discontinued on the advice of the data and safety monitoring boards after a planned adaptive analysis of data from 1398 patients showed that the prespecified stopping criteria for superiority of therapeutic-dose anticoagulation had been reached in both the high and low <span data-style="small-caps">d</span>-dimer cohorts (Table S1 in the <a href="#ap2">Supplementary Appendix</a>). By that time, 2244 patients with moderate disease had undergone randomization. The primary analysis population consisted of 2219 patients (<a href="#f1">Figure 1</a>). Parallel enrollment of patients with severe Covid-19 ran through December 19, 2020, as reported separately.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f1.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/8e88a364-6d92-45a5-b6ec-234dbad89aa5/assets/images/large/nejmoa2105911_f1.jpg" height="2788" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Enrollment, and Randomization, According to Trial Group.</div><div class="notes"><div role="doc-footnote">Trial sites used varying screening and documentation practices during the coronavirus disease 2019 (Covid-19) pandemic to identify eligible patients, as described in the protocol. Of the 13,373 patients who underwent screening, 7202 were assessed for eligibility in the ATTACC platform, 3799 in the ACTIV-4a platform, and 2372 in the REMAP-CAP platform. Under reasons for exclusion from the trial, âotherâ includes not meeting an inclusion criterion (including a lack of diagnosis of Covid-19), an anticipated duration of hospital stay of less than 72 hours, or meeting an exclusion criterion that is not specified here. Data for patients who had severe disease at baseline could be used for covariate adjustment and dynamic borrowing calculations in the primary analysis. The numbers of patients who were randomly assigned to the treatment groups were imbalanced owing to the use of response-adaptive randomization.</div></div></figcaption></figure></div><div role="paragraph">Baseline characteristics were similar in the two treatment groups (<a href="#t1">Table 1</a>), including within each <span data-style="small-caps">d</span>-dimer cohort (Table S2). Patients in the high and unknown <span data-style="small-caps">d</span>-dimer cohorts were generally older and had a higher prevalence of coexisting illnesses than those in low <span data-style="small-caps">d</span>-dimer cohort. Concomitant baseline therapies included antiplatelet agents (in 12% of the patients), glucocorticoids (in 62%), and remdesivir (in 36%).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/70fa6fc0-4f64-4278-9edb-5faf015fba38/assets/images/large/nejmoa2105911_t1.jpg" height="3438" width="1586" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Therapeutic-Dose<br>Anticoagulation<br>(N=1181)</th><th class="txxr-borders">Usual-Care<br>Thromboprophylaxis<br>(N=1050)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age Â±SD â yr</td><td class="xxxx-borders shading">59.0Â±14.1</td><td class="xxxr-borders shading">58.8Â±13.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">713 (60.4)</td><td class="xxxr-borders">597 (56.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group â no./total no. (%)<a href="#t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">622/994 (62.6)</td><td class="xxxr-borders">564/845 (66.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">41/994 (4.1)</td><td class="xxxr-borders shading">43/845 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">219/994 (22.0)</td><td class="xxxr-borders">162/845 (19.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">First Nations or American Indian</td><td class="xxxx-borders shading">118/965 (12.2)</td><td class="xxxr-borders shading">82/819 (10.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">17/1109 (1.5)</td><td class="xxxr-borders">16/968 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders shading">574/1004 (57.2)</td><td class="xxxr-borders shading">537/879 (61.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (IQR)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">29.8 (26.3â34.7)</td><td class="xxxr-borders">30.3 (26.7â34.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Preexisting condition â no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypertension</td><td class="xxxx-borders">546/1023 (53.4)</td><td class="xxxr-borders">447/892 (50.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diabetes mellitus</td><td class="xxxx-borders shading">352/1181 (29.8)</td><td class="xxxr-borders shading">311/1049 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe cardiovascular disease<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">123/1165 (10.6)</td><td class="xxxr-borders">121/1038 (11.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders shading">83/1173 (7.1)</td><td class="xxxr-borders shading">69/1037 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic respiratory disease<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">249/1132 (22.0)</td><td class="xxxr-borders">212/988 (21.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Immunosuppressive disease</td><td class="xxxx-borders shading">105/1143 (9.2)</td><td class="xxxr-borders shading">103/1005 (10.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment â no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Antiplatelet agent<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">148/1140 (13.0)</td><td class="xxxr-borders shading">111/1013 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Remdesivir</td><td class="xxxx-borders">428/1178 (36.3)</td><td class="xxxr-borders">383/1048 (36.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glucocorticoid</td><td class="xxxx-borders shading">479/791 (60.6)</td><td class="xxxr-borders shading">415/656 (63.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Tocilizumab</td><td class="xxxx-borders">6/1178 (0.5)</td><td class="xxxr-borders">7/1048 (0.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Respiratory support â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">None</td><td class="xxxx-borders">156 (13.2)</td><td class="xxxr-borders">123 (11.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low-flow nasal cannula or face mask</td><td class="xxxx-borders shading">789 (66.8)</td><td class="xxxr-borders shading">696 (66.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High-flow nasal cannula</td><td class="xxxx-borders">25 (2.1)</td><td class="xxxr-borders">28 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Noninvasive mechanical ventilation</td><td class="xxxx-borders shading">21 (1.8)</td><td class="xxxr-borders shading">24 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unspecified<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">190 (16.1)</td><td class="xxxr-borders">179 (17.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median laboratory value (IQR)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median <span data-style="small-caps">d</span>-dimer level relative to ULN at trial site</td><td class="xxxx-borders">1.6 (0.9â2.6)</td><td class="xxxr-borders">1.5 (1.0â2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Platelets â per mm<sup>3</sup></td><td class="xxxx-borders shading">221,000 (171,000â290,000)</td><td class="xxxr-borders shading">218,000 (172,500â289,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lymphocytes â per mm<sup>3</sup></td><td class="xxxx-borders">900 (700â1300)</td><td class="xxxr-borders">1000 (700â1400)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Creatinine â mg/dl</td><td class="xxxx-borders shading">0.9 (0.7â1.1)</td><td class="xxxr-borders shading">0.9 (0.7â1.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Platform of enrollment â no. (%)<a href="#t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">ATTACC<a href="#t1fn9" role="doc-noteref">â¡â¡</a></td><td class="xxxx-borders shading">650 (55.0)</td><td class="xxxr-borders shading">509 (48.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">ACTIV-4a</td><td class="xxxx-borders">387 (32.8)</td><td class="xxxr-borders">392 (37.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">REMAP-CAP</td><td class="xxxx-borders shading">144 (12.2)</td><td class="xxxr-borders shading">149 (14.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Country of enrollment â no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">United Kingdom</td><td class="xxxx-borders shading">95/1181 (8.0)</td><td class="xxxr-borders shading">103/1050 (9.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">United States</td><td class="xxxx-borders">573/1181 (48.5)</td><td class="xxxr-borders">507/1050 (48.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Canada</td><td class="xxxx-borders shading">102/1181 (8.6)</td><td class="xxxr-borders shading">83/1050 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Brazil</td><td class="xxxx-borders">234/1181 (19.8)</td><td class="xxxr-borders">209/1050 (19.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Other<a href="#t1fn10" role="doc-noteref">Â§Â§</a></td><td class="xbxx-borders shading">177/1181 (15.0)</td><td class="xbxr-borders shading">148/1050 (14.1)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Listed are data that were included in the analysis involving patients with moderate severity of coronavirus disease 2019 (Covid-19). The denominators of patients in the anticoagulation group and the thrombophylaxis group are unequal owing to response-adaptive randomization. The baseline characteristics of the patients according to <span data-style="small-caps">d</span>-dimer level are provided in Table S2 in the <a href="#ap2">Supplementary Appendix</a>. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ULN denotes upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Race or ethnic group was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">Severe cardiovascular disease was defined as a baseline history of heart failure, myocardial infarction, coronary artery disease, peripheral arterial disease, or cerebrovascular disease (stroke or transient ischemic attack) in the ATTACC (Antithrombotic Therapy to Ameliorate Complications of Covid-19) and ACTIV-4a (A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19) platforms and as a baseline history of New York Heart Association class IV symptoms in the REMAP-CAP platform (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">Chronic respiratory disease was defined as a baseline history of asthma, chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, primary lung cancer, pulmonary hypertension, active tuberculosis, or the receipt of home oxygen therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">Not listed are 74 patients who were coenrolled in the REMAP-CAP Antiplatelet Domain (39 in the anticoagulation group and 35 in the thromboprophylaxis group).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">In REMAP-CAP, levels of oxygen support (including no support) below the level of high-flow nasal cannula were not reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="t1fn8" role="paragraph">The relative proportion of patients who were randomly assigned in each platform was imbalanced owing to implementation of response-adaptive randomization in ATTACC on December 15, 2020.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡â¡</div><div id="t1fn9" role="paragraph">A total of 215 patients who were enrolled in the ATTACC platform were funded by the ACTIV4a platform by the National Heart, Lung, and Blood Institute.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§Â§</div><div id="t1fn10" role="paragraph">Other participating countries were Mexico, Nepal, Australia, the Netherlands, and Spain.</div></div></div></figcaption></figure></div><div role="paragraph">Initial adherence to the protocol-assigned anticoagulation dose after randomization was 88.3% in the therapeutic-dose anticoagulation group and 98.3% in the thromboprophylaxis group (Table S3). Of the 1093 patients in the therapeutic-dose anticoagulation group with available data, 1035 (94.7%) received a low-molecular-weight heparin, most commonly enoxaparin. Among the 855 patients in the thromboprophylaxis group with available data, 613 (71.7%) received a low dose of a thromboprophylactic drug and 227 (26.5%) received an intermediate dose.</div></section><section id="sec-2-2"><h3>Primary Outcome</h3><div role="paragraph">Among 2219 participants with moderate disease, the posterior probability that therapeutic-dose anticoagulation increased organ supportâfree days as compared with usual-care thromboprophylaxis was 98.6% (median adjusted odds ratio, 1.27; 95% credible interval, 1.03 to 1.58) (<a href="#t2">Table 2</a>). Of the 1048 patients in the usual-care thromboprophylaxis group, 801 (76.4%) survived until hospital discharge without receipt of organ support during the first 21 days, as compared with 939 of 1171 patients (80.2%) in the therapeutic-dose anticoagulation group. The median adjusted absolute difference in this value was 4.0 percentage points (95% credible interval, 0.5 to 7.2), favoring the anticoagulation group. Because the majority of patients in the two treatment groups survived until hospital discharge without receipt of ICU-level organ support, the median value for organ supportâfree days was 22 in both groups (<a href="#f2">Figure 2</a> and Fig. S1). Accordingly, the proportion of patients in each treatment group who survived until hospital discharge without receipt of organ support (22 on the ordinal scale) is reported.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f2.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/7cea410f-d2eb-4f0d-9deb-f6321921de30/assets/images/large/nejmoa2105911_f2.jpg" height="2421" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Days without Organ Support among All the Patients with Moderate Disease.</div><div class="notes"><div role="doc-footnote">Panel A shows the distribution of organ supportâfree days among all the patients with moderate disease. The ordinal scale includes a score of â1 (in-hospital death, the worst possible outcome), a score of 0 to 21 (the numbers of days alive without organ support), and a score of 22 (survival until hospital discharge without receipt of organ support, the best possible outcome). The difference in the height of the two curves at any point represents the difference in the cumulative probability of having a value for days without organ support of less than or equal to that point on the x axis. Panel B shows the number of days without organ support as horizontally stacked proportions of patients in the two treatment groups, with the following possible outcomes: in-hospital death with or without the receipt of organ support (dark red, the worst possible outcome, corresponding to a score of â1 on the ordinal scale); survival with organ support provided in an intensive care unit (ICU) (red-to-blue gradient shading based on the number of days alive without organ support; intermediate outcome, corresponding to a score of 0 to 21 on the ordinal scale); and survival until hospital discharge without ICU-level organ support (dark blue, the best possible outcome, corresponding to a score of 22 on the ordinal scale).</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/36eaacfe-d91c-4a1f-adf0-a041ba9f14ed/assets/images/large/nejmoa2105911_t2.jpg" height="1654" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Therapeutic-Dose Anticoagulation</th><th class="txxx-borders">Usual-Care Thrombo-prophylaxis</th><th class="txxx-borders">Adjusted Difference in Risk<br>(95% Credible Interval)<a href="#t2fn2" role="doc-noteref">â </a></th><th class="txxx-borders">Adjusted<br>Odds Ratio<br>(95% Credible Interval)<a href="#t2fn3" role="doc-noteref">â¡</a></th><th class="txxr-borders">Probability of Superiority of Therapeutic-Dose Anticoagulation</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>no. of patients/total no. (%)</span></th><th class="xxxx-borders">percentage points</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patients with moderate disease</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Overall group<a href="#t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">939/1171 (80.2)</td><td class="xxxx-borders">801/1048 (76.4)</td><td class="xxxx-borders">4.0<br>(0.5 to 7.2)</td><td class="xxxx-borders">1.27<br>(1.03â1.58)</td><td class="xxxr-borders">98.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><span data-style="small-caps">d</span>-dimer cohort<a href="#t2fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High level</td><td class="xxxx-borders">264/339 (77.9)</td><td class="xxxx-borders">210/291 (72.2)</td><td class="xxxx-borders">5.1<br>(0.0 to 9.9)</td><td class="xxxx-borders">1.31<br>(1.00â1.76)</td><td class="xxxr-borders">97.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low level</td><td class="xxxx-borders shading">463/570 (81.2)</td><td class="xxxx-borders shading">403/505 (79.8)</td><td class="xxxx-borders shading">3.0<br>(â1.2 to 6.3)</td><td class="xxxx-borders shading">1.22<br>(0.93â1.57)</td><td class="xxxr-borders shading">92.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Unknown level</td><td class="xbxx-borders">212/262 (80.9)</td><td class="xbxx-borders">188/252 (74.6)</td><td class="xbxx-borders">4.9<br>(0.00 to 9.9)</td><td class="xbxx-borders">1.32<br>(1.00â1.86)</td><td class="xbxr-borders">97.3</td></tr></tbody></table></div><figcaption><div class="caption">Primary Outcome of Organ SupportâFree Days.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The primary outcome was organ supportâfree days, evaluated on an ordinal scale that combined in-hospital death and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. Because the majority of patients in the two treatment groups survived until hospital discharge without receipt of critical careâlevel organ support, the median value for organ supportâfree days was 22 in both groups. Accordingly, the proportion of patients in each treatment group who survived until hospital discharge without receipt of organ support (22 on the ordinal scale) is reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">The adjusted difference in risk is based on the event frequency in the usual-care thromboprophylaxis group and the odds ratio after adjustment for age, sex, site, <span data-style="small-caps">d</span>-dimer group, and enrollment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">The odds ratio is for the therapeutic-dose anticoagulation group as compared with the usual-care thromboprophylaxis group. The odds ratios are adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period, which may be imbalanced due to the use of response-adaptive randomization.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t2fn4" role="paragraph">This model assumes a single treatment effect in all the patients with moderate disease regardless of the baseline <span data-style="small-caps">d</span>-dimer level. Dynamic borrowing of information on the treatment effect from patients who had severe illness at baseline was permitted, in which similar treatment effects were grouped together on the basis of their degree of similarity. Results from a sensitivity analysis assuming independent treatment effects between disease-severity cohorts are provided in Table S5 in the <a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t2fn5" role="paragraph">The primary adaptive model estimated treatment effects with the use of a Bayesian hierarchical approach in the following groups: patients with severe disease and those with moderate disease stratified according to their baseline high <span data-style="small-caps">d</span>-dimer level (â¥2 times the ULN, low <span data-style="small-caps">d</span>-dimer level (&lt;2 times the ULN), or unknown <span data-style="small-caps">d</span>-dimer level. This model permitted dynamic borrowing across illness-severity and <span data-style="small-caps">d</span>-dimer cohorts, in which similar treatment effects are grouped together on the basis of their degree of similarity. Accordingly, observations about treatment effect are shared between groups. Results from a sensitivity analysis assuming independent treatment effects among <span data-style="small-caps">d</span>-dimerâdefined cohorts are also provided in Table S5.</div></div></div></figcaption></figure></div><div role="paragraph">In the primary adaptive analysis groups, the final posterior probability for superiority of therapeutic-dose anticoagulation as compared with usual-care thromboprophylaxis was 97.3% in the high <span data-style="small-caps">d</span>-dimer cohort, 92.9% in the low <span data-style="small-caps">d</span>-dimer cohort, and 97.3% in the cohort with an unknown <span data-style="small-caps">d</span>-dimer level (<a href="#t2">Table 2</a> and Fig. S1). The results were consistent in sensitivity analyses (Tables S4 and S5).</div><div role="paragraph">Among all the patients with moderate disease, the treatment effect did not vary meaningfully according to age, level of respiratory support at enrollment, or dose of thromboprophylactic drugs. There was a 95.2% probability that the odds ratio associated with therapeutic-dose anticoagulation was higher in men than in women (Fig. S2).</div></section><section id="sec-2-3"><h3>Secondary Outcomes</h3><div role="paragraph">Secondary outcomes are shown in <a href="#t3">Table 3</a>, Table S6, and Figure S3. In the overall cohort of patients with moderate disease, the posterior probability that therapeutic-dose anticoagulation increased survival until hospital discharge as compared with thromboprophylaxis was 87.1% (median adjusted odds ratio, 1.21; 95% credible interval, 0.87 to 1.68), for a median adjusted between-group difference of 1.3 percentage points (95% credible interval, â1.1 to 3.2). The posterior probabilities that patients in the therapeutic-dose anticoagulation group were more likely to survive without organ support or survive without invasive mechanical ventilation at 28 days were 99.1% and 92.2%, respectively.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t3.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/0e9277d1-2b21-4a0f-b0be-26136f1eec7a/assets/images/large/nejmoa2105911_t3.jpg" height="1562" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Therapeutic-Dose Anticoagulation</th><th class="txxx-borders">Usual-Care <br>Thromboprophylaxis</th><th class="txxx-borders">Adjusted<br>Difference in Risk<br>(95% Credible Interval)<a href="#t3fn2" role="doc-noteref">â </a></th><th class="txxx-borders">Adjusted<br>Odds Ratio<br>(95% Credible Interval)<a href="#t3fn3" role="doc-noteref">â¡</a></th><th class="txxr-borders">Probability of Effect of Therapeutic-Dose Anticoagulation</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>no. of patients/total no. (%)</span></th><th class="xxxx-borders">percentage points</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Survival until hospital discharge</td><td class="xxxx-borders shading">1085/1171 (92.7)</td><td class="xxxx-borders shading">962/1048 (91.8)</td><td class="xxxx-borders shading">1.3<br>(â1.1 to 3.2)</td><td class="xxxx-borders shading">1.21<br>(0.87 to 1.68)<a href="#t3fn4" role="doc-noteref">Â§</a></td><td class="xxxr-borders shading">87.1<a href="#t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Survival without organ support at 28 days<a href="#t3fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">932/1175 (79.3)</td><td class="xxxx-borders">789/1046 (75.4)</td><td class="xxxx-borders">4.5<br>(0.9 to 7.7)</td><td class="xxxx-borders">1.30<br>(1.05 to 1.61)</td><td class="xxxr-borders">99.1<a href="#t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Progression to intubation or death<a href="#t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">129/1181 (10.9)</td><td class="xxxx-borders shading">127/1050 (12.1)</td><td class="xxxx-borders shading">â1.9<br>(â4.1 to 0.7)</td><td class="xxxx-borders shading">0.82<br>(0.63 to 1.07)</td><td class="xxxr-borders shading">92.2<a href="#t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major thrombotic event or death</td><td class="xxxx-borders">94/1180 (8.0)</td><td class="xxxx-borders">104/1046 (9.9)</td><td class="xxxx-borders">â2.6<br>(â4.4 to â0.2)</td><td class="xxxx-borders">0.72<br>(0.53 to 0.98)</td><td class="xxxr-borders">98.0<a href="#t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Major thrombotic event</td><td class="xxxx-borders shading">13/1180 (1.1)</td><td class="xxxx-borders shading">22/1046 (2.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death in hospital</td><td class="xxxx-borders">86/1180 (7.3)</td><td class="xxxx-borders">86/1046 (8.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Major bleeding</td><td class="xbxx-borders shading">22/1180 (1.9)</td><td class="xbxx-borders shading">9/1047 (0.9)</td><td class="xbxx-borders shading">0.7<br>(â0.1 to 2.3)</td><td class="xbxx-borders shading">1.80<br>(0.90 to 3.74)</td><td class="xbxr-borders shading">95.5<a href="#t3fn8" role="doc-noteref">â â </a></td></tr></tbody></table></div><figcaption><div class="caption">Secondary Outcomes among All Patients with Moderate Disease.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Secondary end points were modeled without dynamic borrowing. In these analyses, a single treatment effect was assumed regardless of the <span data-style="small-caps">d</span>-dimer level. Additional secondary end points, including those categorized according to the <span data-style="small-caps">d</span>-dimer cohort, are provided in Table S6.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">The adjusted difference in risk is based on the event rate in the usual-care thromboprophylaxis group and the odds ratio after adjustment for age, sex, site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t3fn3" role="paragraph">The odds ratio is for the therapeutic-dose anticoagulation group as compared with the usual-care thromboprophylaxis group. The odds ratios are adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period, which may be imbalanced due to the use of response-adaptive randomization.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t3fn4" role="paragraph">In a model that included borrowing of information on treatment effect from patients with severe disease, the median adjusted odds ratio for survival until hospital discharge was 1.18 (95% credible interval, 0.86 to 1.63), with a posterior probability of superiority of 84.4%.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t3fn5" role="paragraph">In this category, the probability of superiority is shown.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t3fn6" role="paragraph">Survival without organ support at 28 days was modeled as a dichotomous outcome. Similar results were obtained after the exclusion of 52 patients who were receiving organ support at baseline (median adjusted odds ratio, 1.30; 95% credible interval, 1.06 to 1.62), with a posterior probability of superiority of 99.3%.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">Progression to intubation or death was modeled as an ordinal outcome with death as the worst possible outcome.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="t3fn8" role="paragraph">For major bleeding, the probability of inferiority is shown.</div></div></div></figcaption></figure></div><div role="paragraph">A major thrombotic event or in-hospital death occurred in 94 of 1180 patients (8.0%) in the therapeutic-dose anticoagulation group and in 104 of 1046 patients (9.9%) in the thromboprophylaxis group (<a href="#t3">Table 3</a> and Tables S6 and S7). The analysis of the end point incorporating the occurrence of deep venous thrombosis had similar results. Major bleeding occurred in 22 of 1180 patients (1.9%) in the therapeutic-dose anticoagulation group and in 9 of 1047 (0.9%) in the usual-care thromboprophylaxis group (Table S8). Fatal bleeding occurred in 3 patients in the anticoagulation group and in 1 patient in the thromboprophylaxis group. There were no episodes of intracranial bleeding or confirmed HIT.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In noncritically ill patients hospitalized with Covid-19, therapeutic-dose anticoagulation with heparin (most commonly, low-molecular-weight heparin) increased the probability of survival until hospital discharge with a reduced need for ICU-level organ support at 21 days as compared with usual-care thromboprophylaxis. Therapeutic-dose anticoagulation was beneficial regardless of the patientâs baseline <span data-style="small-caps">d</span>-dimer level. Major bleeding occurred more frequently in the anticoagulation group (1.9% vs. 0.9%). On the basis of these findings, for every 1000 hospitalized patients with moderate disease, an initial strategy of therapeutic-dose anticoagulation, as compared with usual-care thromboprophylaxis, would be anticipated to result in the survival of 40 additional patients until hospital discharge without organ support at the expense of 7 additional major bleeding events. Absolute treatment benefits were more apparent in the high <span data-style="small-caps">d</span>-dimer cohort than in the low <span data-style="small-caps">d</span>-dimer cohort. Patients in the high <span data-style="small-caps">d</span>-dimer cohort were generally older and had a higher prevalence of coexisting illnesses than those in the low <span data-style="small-caps">d</span>-dimer cohort.</div><div role="paragraph">Several cohort studies have shown a favorable association between anticoagulant use and survival from Covid-19.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21 r22" id="body-ref-r22" href-manipulated="true">20-22</a></sup> Because SARS-CoV-2 infection incites a dysregulated inflammatory response that may lead to activation of coagulation<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup> and potentially contribute to organ failure,<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25 r26" id="body-ref-r26" href-manipulated="true">24-26</a></sup> heparins may reduce the use of organ support through antithrombotic, antiinflammatory, and potentially antiviral mechanisms.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8 r9 r10 r27" id="body-ref-r27" href-manipulated="true">8â10,27</a></sup></div><div role="paragraph">In contrast to the benefit we found in noncritically ill patients, a parallel analysis from the same multiplatform trial showed that empirical therapeutic-dose anticoagulation was not beneficial in critically ill patients (i.e., those receiving ICU-level care at enrollment).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-2" href-manipulated="true" aria-label="Reference 19">19</a></sup> In a separate randomized trial involving critically ill patients with Covid-19, intermediate-dose heparin was likewise not beneficial.<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> It is possible that therapeutic-dose heparin cannot influence the cascade of inflammation, thrombosis, and organ injury in patients with advanced disease.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29 r30 r31" id="body-ref-r31" href-manipulated="true">29-31</a></sup> It is also possible that differences in the patient populations, aside from illness severity, may have contributed to these findings.</div><div role="paragraph">In our multiplatform trial, we used an adaptive Bayesian design that allowed for trial conclusions to be reached simultaneously or sequentially in groups defined according to illness severity and <span data-style="small-caps">d</span>-dimer level through periodic adaptive analyses. A statistical method of dynamic borrowing was incorporated to enable the investigators to reach conclusions more quickly across the <span data-style="small-caps">d</span>-dimer stopping cohorts in which the estimates of treatment effect were similar and to mitigate the influence of outlying treatment effects by shrinking similar treatment estimates together. Response-adaptive randomization allowed blinded randomization probabilities to be modified as evidence about treatment effects was accrued throughout the trial. Since response-adaptive randomization may lead to imbalances in baseline covariates between treatment groups over time, the primary models were necessarily adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period. Therefore, absolute between-group differences in risk that are based on adjusted treatment effects and the observed frequencies of control events are presented. The adjusted absolute between-group difference in outcomes that is presented is a median, so patients at higher baseline risk may derive greater absolute benefit.</div><div role="paragraph">The open-label design of the trial represents a potential limitation, although the primary outcome involving survival and receipt of organ support was selected to minimize bias and to function across a spectrum of illness severity. The potential for ascertainment bias cannot be excluded for the secondary outcomes of major bleeding or thrombosis. This factor, along with the absence of protocol-specified screening for venous thrombosis and the exclusion of patients at increased bleeding risk, may have contributed to a lower incidence of thrombotic events than has been reported previously.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup> Although the platforms varied slightly in their classification of illness severity, the majority of patients who were receiving organ support at baseline were included in the analysis involving patients with severe disease.<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19-3" href-manipulated="true" aria-label="Reference 19">19</a></sup> Because we did not have detailed screening data, we were not able to specify the most common reasons for exclusion from the trial, other than a high bleeding risk or a clinical indication for anticoagulation. Thus, it is not possible to fully assess the generalizability of our findings. Finally, the treatment effect was attenuated in the final analysis relative to the adaptive stopping results; nevertheless, a high probability of benefit persisted.</div><div role="paragraph">Among noncritically ill patients hospitalized with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival until hospital discharge with reduced use of ICU-level organ support as compared with usual-care thromboprophylaxis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="writing-committee" role="paragraph">The members of the executive writing committee are as follows: Patrick R. Lawler, M.D., M.P.H., Ewan C. Goligher, M.D., Ph.D., Jeffrey S. Berger, M.D., Matthew D. Neal, M.D., Bryan J. McVerry, M.D, Jose C. Nicolau, M.D., Ph.D., Michelle N. Gong, M.D., Marc Carrier, M.D., Robert S. Rosenson, M.D., Harmony R. Reynolds, M.D., Alexis F. Turgeon, M.D., Jorge Escobedo, M.D., David T. Huang, M.D., M.P.H., Charlotte A. Bradbury, M.B., Ch.B., Ph.D., Brett L. Houston, M.D., Lucy Z. Kornblith, M.D., Anand Kumar, M.D., Susan R. Kahn, M.D., Mary Cushman, M.D., Zoe McQuilten, Ph.D., Arthur S. Slutsky, M.D., Keri S. Kim, Pharm.D., Anthony C. Gordon, M.B., B.S., M.D., Bridget-Anne Kirwan, Ph.D., Maria M. Brooks, Ph.D., Alisa M. Higgins, Ph.D., Roger J. Lewis, M.D., Ph.D., Elizabeth Lorenzi, Ph.D., Scott M. Berry, Ph.D., Lindsay R. Berry, Ph.D., Derek C. Angus, M.D., M.P.H., Colin J. McArthur, M.B., Ch.B., Steven A. Webb, M.P.H., Ph.D., Michael E. Farkouh, M.D., Judith S. Hochman, M.D., and Ryan Zarychanski, M.D.</div><div data-type="writing-committee" role="paragraph">The members of the block writing committee are as follows: Aaron W. Aday, M.D., Farah Al-Beidh, Ph.D., Djillali Annane, M.D., Ph.D., Yaseen M. Arabi, M.D., Diptesh Aryal, M.D., Lisa Baumann Kreuziger, M.D., Abi Beane, Ph.D., Zahra Bhimani, M.P.H., Shailesh Bihari, Ph.D., Henny H. Billett, M.D., Lindsay Bond, H.B.Sc., Marc Bonten, Ph.D., Frank Brunkhorst, M.D., Meredith Buxton, Ph.D., Adrian Buzgau, B.A.S., Lana A. Castellucci, M.D., Sweta Chekuri, M.D., Jen-Ting Chen, M.D., Allen C. Cheng, Ph.D., Tamta Chkhikvadze, M.D., Benjamin Coiffard, M.D., Todd W. Costantini, M.D., Sophie de Brouwer, Ph.D., Lennie P.G. Derde, M.D., Ph.D., Michelle A. Detry, Ph.D., Abhijit Duggal, M.D., M.P.H., VladimÃ­r DÅ¾avÃ­k, M.D., Mark B. Effron, M.D., Lise J. Estcourt, M.B., B.Chir., D.Phil., Brendan M. Everett, M.D., M.P.H., Dean A. Fergusson, Ph.D., Mark Fitzgerald, Ph.D., Robert A. Fowler, M.D., Jean P. Galanaud, M.D., Benjamin T. Galen, M.D., Sheetal Gandotra, M.D., Sebastian GarcÃ­a-Madrona, M.D., Timothy D. Girard, M.D., Lucas C. Godoy, M.D., Andrew L. Goodman, M.D., Herman Goossens, M.D., Cameron Green, M.Sc., Yonatan Y. Greenstein, M.D., Peter L. Gross, M.D., Naomi M. Hamburg, M.D., Rashan Haniffa, Ph.D., George Hanna, M.D., Nicholas Hanna, M.D., Sheila M. Hegde, M.D., M.P.H., Carolyn M. Hendrickson, M.D., R. Duncan Hite, M.D., Alexander A. Hindenburg, M.D., Aluko A. Hope, M.D., James M. Horowitz, M.D., Christopher M. Horvat, M.D., M.H.A., Kristin Hudock, M.D., Beverley J. Hunt, M.D., Mansoor Husain, M.D., Robert C. Hyzy, M.D., Vivek N. Iyer, M.D., M.P.H., Jeffrey R. Jacobson, M.D., Devachandran Jayakumar, M.D., Norma M. Keller, M.D., Akram Khan, M.D., Yuri Kim, M.D., Ph.D., Andrei L. Kindzelski, M.D., Ph.D., Andrew J. King, Ph.D., M. Margaret Knudson, M.D., Aaron E. Kornblith, M.D., Vidya Krishnan, M.D., M.H.S., Matthew E. Kutcher, M.D., Michael A. Laffan, D.M., Francois Lamontagne, M.D., GrÃ©goire Le Gal, M.D., Ph.D., Christine M. Leeper, M.D., Eric S. Leifer, Ph.D., George Lim, M.D., Felipe Gallego Lima, M.D., Kelsey Linstrum, M.S., Edward Litton, Ph.D., Jose Lopez-Sendon, Ph.D., Jose L. Lopez-Sendon Moreno, M.D., Sylvain A. Lother, M.D., Saurabh Malhotra, M.D., M.P.H., Miguel Marcos, Ph.D., AndrÃ©a Saud Marinez, Pharm.D., John C. Marshall, M.D., Nicole Marten, R.N., Michael A. Matthay, M.D., Daniel F. McAuley, M.D., Emily G. McDonald, M.D., Anna McGlothlin, Ph.D., Shay P. McGuinness, M.B., Ch.B., Saskia Middeldorp, M.D., Ph.D., Stephanie K. Montgomery, M.Sc., Steven C. Moore, M.D., Raquel Morillo Guerrero, Ph.D., Paul R. Mouncey, M.Sc., Srinivas Murthy, M.D., Girish B. Nair, M.D., Rahul Nair, M.D., Alistair D. Nichol, M.B., Ph.D., Brenda Nunez-Garcia, B.A., Ambarish Pandey, M.D., Pauline K. Park, M.D., Rachael L. Parke, Ph.D., Jane C. Parker, B.N., Sam Parnia, M.D., Ph.D., Jonathan D. Paul, M.D., Yessica S. PÃ©rez GonzÃ¡lez, M.D., Mauricio Pompilio, Ph.D., Matthew E. Prekker, M.D., M.P.H., John G. Quigley, M.D., Natalia S. Rost, M.D., Kathryn Rowan, Ph.D., Fernanda O. Santos, M.D., Marlene Santos, M.D., Mayler Olombrada Santos, M.Sc., Lewis Satterwhite, M.D., Christina T. Saunders, Ph.D., Roger E.G. Schutgens, M.D., Ph.D., Christopher W. Seymour, M.D., Deborah M. Siegal, M.D., Delcio G. Silva, Jr., M.Med., Manu Shankar-Hari, Ph.D., John P. Sheehan, M.D., Aneesh B. Singhal, M.D., Dayna Solvason, Simon J. Stanworth, D.Phil., Tobias Tritschler, M.D., Anne M. Turner, M.P.H., Wilma van Bentum-Puijk, M.Sc., Frank L. van de Veerdonk, M.D., Ph.D., Sean van Diepen, M.D., Gloria Vazquez-Grande, M.D., Lana Wahid, M.D., Vanessa Wareham, H.B.Sc., Bryan J. Wells, M.D., R. Jay Widmer, M.D., Ph.D., Jennifer G. Wilson, M.D., Eugene Yuriditsky, M.D., and Fernando G. Zampieri, M.D., Ph.D.</div><div data-type="disclaimer" role="paragraph">The views expressed in this article are those of the authors and do not necessarily reflect the view of the National Health Service (in the United Kingdom [U.K.]), the U.K. National Institute for Health Research, the U.K. Department of Health and Social Care, or the National Institutes of Health in the United States.</div><div data-type="published/updated" role="paragraph">This article was published on August 4, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">The ATTACC platform was supported by grants from the Canadian Institutes of Health Research, LifeArc Foundation, Thistledown Foundation, Research Manitoba, Ontario Ministry of Health, Peter Munk Cardiac Centre, CancerCare Manitoba Foundation, and Victoria General Hospital Foundation. The ACTIV-4a platform was sponsored by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH) (grant numbers, OTA-20-011 and 1OT2HL156812-01). The pilot program (PROTECT) was funded in part by a grant (UL1TR001445) from the New York University Clinical and Translational Science Award program, supported by the National Center for Advancing Translational Sciences of the NIH. The REMAP-CAP platform was supported by the European Union through FP7-HEALTH-2013-INNOVATION: the Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) consortium (602525) and the Horizon 2020 research and innovation program: the Rapid European Covid-19 Emergency Research response (RECOVER) consortium (101003589); by the Australian National Health and Medical Research Council (APP1101719 and APP1116530), the Health Research Council of New Zealand (16/631), the Canadian Institutes of Health Research (Strategy for Patient-Oriented Research Innovative Clinical Trials Program Grant [158584] and Covid-19 Rapid Research Operating Grant [447335]), the U.K. National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (CTN 2014-012), the Learning While Doing Program at the University of Pittsburgh Medical Center, the Breast Cancer Research Foundation, the French Ministry of Health (PHRC-20-0147), the Minderoo Foundation, Amgen, Eisai, the Global Coalition for Adaptive Research, and the Wellcome Trust Innovations Project (215522). Dr. Goligher is the recipient of an Early Career Investigator award from the Canadian Institutes of Health Research (grant AR7-162822). Dr. Gordon is supported by an NIHR Research Professorship (RP-2015-06-18), Dr. Shankar-Hari by an NIHR Clinician Scientist Fellowship (CS-2016-16-011), and Dr. Turgeon by a Canada Research Chair (Tier 2). Dr. Zarychanski is the recipient of the Lyonel G. Israels Research Chair in Hematology (University of Manitoba).</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their families who participated in this trial and the members of the data and safety monitoring board for each platform.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2105911_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_research-summary.pdf" download="nejmoa2105911_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2105911_research-summary.pdf" data-doi="10.1056/NEJMoa2105911">Download</a></li><li>722.42 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2105911_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_protocol.pdf" download="nejmoa2105911_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2105911_protocol.pdf" data-doi="10.1056/NEJMoa2105911">Download</a></li><li>7.49 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2105911_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_appendix.pdf" download="nejmoa2105911_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2105911_appendix.pdf" data-doi="10.1056/NEJMoa2105911">Download</a></li><li>1.75 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2105911_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_disclosures.pdf" download="nejmoa2105911_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2105911_disclosures.pdf" data-doi="10.1056/NEJMoa2105911">Download</a></li><li>2.17 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2105911_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2105911/suppl_file/nejmoa2105911_data-sharing.pdf" download="nejmoa2105911_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2105911_data-sharing.pdf" data-doi="10.1056/NEJMoa2105911">Download</a></li><li>70.44 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. <em>Lancet</em> 2020;395:1054-1062.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30566-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32171076/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522650100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+course+and+risk+factors+for+mortality+of+adult+inpatients+with+COVID-19+in+Wuhan%2C+China%3A+a+retrospective+cohort+study.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1054-1062&amp;doi=10.1016%2FS0140-6736%2820%2930566-3&amp;pmid=32171076" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Mody A, Lyons PG, Vazquez Guillamet C, et al. The clinical course of coronavirus disease 2019 in a US hospital system: a multistate analysis. <em>Am J Epidemiol</em> 2021;190:539-552.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwaa286" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33351077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000644497600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+clinical+course+of+coronavirus+disease+2019+in+a+US+hospital+system%3A+a+multistate+analysis.&amp;publication_year=2021&amp;journal=Am+J+Epidemiol&amp;pages=539-552&amp;doi=10.1093%2Faje%2Fkwaa286&amp;pmid=33351077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. <em>JAMA</em> 2020;323:2052-2059.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.6775" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32320003/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538023900036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=2052-2059&amp;doi=10.1001%2Fjama.2020.6775&amp;pmid=32320003" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. <em>BMJ</em> 2020;369:m1923-m1923.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.m1923" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32444358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538336800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence%2C+clinical+outcomes%2C+and+transmission+dynamics+of+severe+coronavirus+disease+2019+in+California+and+Washington%3A+prospective+cohort+study.&amp;publication_year=2020&amp;journal=BMJ&amp;pages=m1923-m1923&amp;doi=10.1136%2Fbmj.m1923&amp;pmid=32444358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. <em>Ann Intern Med</em> 2021;174:33-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M20-3905" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32960645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000619485200019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patient+trajectories+among+persons+hospitalized+for+COVID-19%3A+a+cohort+study.&amp;publication_year=2021&amp;journal=Ann+Intern+Med&amp;pages=33-41&amp;doi=10.7326%2FM20-3905&amp;pmid=32960645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. <em>JAMA</em> 2020;324:799-801.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.13372" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32702090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568230000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Thrombosis+in+hospitalized+patients+with+COVID-19+in+a+New+York+City+health+system.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=799-801&amp;doi=10.1001%2Fjama.2020.13372&amp;pmid=32702090" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] associated with a poor clinical outcome. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] thrombosis and a poor clinical outcome. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. <em>CMAJ</em> 2020;192(40):E1156-E1161.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1503/cmaj.201240" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32816822/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581747900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticipating+and+managing+coagulopathy+and+thrombotic+manifestations+of+severe+COVID-19.&amp;publication_year=2020&amp;journal=CMAJ&amp;pages=E1156-E1161&amp;doi=10.1503%2Fcmaj.201240&amp;pmid=32816822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. <em>Cell</em> 2020;183(4):1043.e15-1057.e15.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.09.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32970989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588640900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+depends+on+cellular+heparan+sulfate+and+ACE2.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1043.e15-1057.e15&amp;doi=10.1016%2Fj.cell.2020.09.033&amp;pmid=32970989" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. <em>EBioMedicine</em> 2020;59:102969-102969.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ebiom.2020.102969" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32853989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000575450100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Beneficial+non-anticoagulant+mechanisms+underlying+heparin+treatment+of+COVID-19+patients.&amp;publication_year=2020&amp;journal=EBioMedicine&amp;pages=102969-102969&amp;doi=10.1016%2Fj.ebiom.2020.102969&amp;pmid=32853989" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Mycroft-West CJ, Su D, Pagani I, et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. <em>Thromb Haemost</em> 2020;120:1700-1715.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0040-1721319" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33368089/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000601223000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin+inhibits+cellular+invasion+by+SARS-CoV-2%3A+structural+dependence+of+the+interaction+of+the+spike+S1+receptor-binding+domain+with+heparin.&amp;publication_year=2020&amp;journal=Thromb+Haemost&amp;pages=1700-1715&amp;doi=10.1055%2Fs-0040-1721319&amp;pmid=33368089" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Chowdhury JF, Moores LK, Connors JM. Anticoagulation in hospitalized patients with Covid-19. <em>N Engl J Med</em> 2020;383:1675-1678.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMclde2028217&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33085867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582579100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation+in+hospitalized+patients+with+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1675-1678&amp;doi=10.1056%2FNEJMclde2028217&amp;pmid=33085867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Short SAP, Gupta S, Brenner SK, et al. d-Dimer and death in critically ill patients with coronavirus disease 2019. <em>Crit Care Med</em> 2021;49(5):e500-e511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000004917" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33591017/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000640883100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=d-Dimer+and+death+in+critically+ill+patients+with+coronavirus+disease+2019.&amp;publication_year=2021&amp;journal=Crit+Care+Med&amp;pages=e500-e511&amp;doi=10.1097%2FCCM.0000000000004917&amp;pmid=33591017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. <em>Crit Care</em> 2020;24:559-559.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13054-020-03273-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32938471/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000574593700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+published+guidelines+for+management+of+coagulopathy+and+thrombosis+in+critically+ill+patients+with+COVID+19%3A+implications+for+clinical+practice+and+future+investigations.&amp;publication_year=2020&amp;journal=Crit+Care&amp;pages=559-559&amp;doi=10.1186%2Fs13054-020-03273-y&amp;pmid=32938471" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Rosovsky RP, Sanfilippo KM, Wang TF, et al. Anticoagulation practice patterns in COVID-19: a global survey. <em>Res Pract Thromb Haemost</em> 2020;4:969-983.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rth2.12414" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32838111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562909000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation+practice+patterns+in+COVID-19%3A+a+global+survey.&amp;publication_year=2020&amp;journal=Res+Pract+Thromb+Haemost&amp;pages=969-983&amp;doi=10.1002%2Frth2.12414&amp;pmid=32838111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Houston BL, Lawler PR, Goligher EC, et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. <em>Clin Trials</em> 2020;17:491-500.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774520943846" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32815416/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561686100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-Thrombotic+Therapy+to+Ameliorate+Complications+of+COVID-19+%28ATTACC%29%3A+study+design+and+methodology+for+an+international%2C+adaptive+Bayesian+randomized+controlled+trial.&amp;publication_year=2020&amp;journal=Clin+Trials&amp;pages=491-500&amp;doi=10.1177%2F1740774520943846&amp;pmid=32815416" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and Design. <em>Ann Am Thorac Soc</em> 2020;17:879-891.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1513/AnnalsATS.202003-192SD" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32267771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000546620500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+REMAP-CAP+%28Randomized+Embedded+Multifactorial+Adaptive+Platform+for+Community-acquired+Pneumonia%29+study.+Rationale+and+Design.&amp;publication_year=2020&amp;journal=Ann+Am+Thorac+Soc&amp;pages=879-891&amp;doi=10.1513%2FAnnalsATS.202003-192SD&amp;pmid=32267771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. <em>N Engl J Med</em> 2021;385:777-789.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMoa2103417&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34351722/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000683387200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+anticoagulation+with+heparin+in+critically+ill+patients+with+Covid-19&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=777-789&amp;doi=10.1056%2FNEJMoa2103417&amp;pmid=34351722" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] severe Covid-19 are reported separately. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] December 19, 2020, as reported separately. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Schulman S, Kearon C, the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <em>J Thromb Haemost</em> 2005;3:692-694.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2005.01204.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15842354/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000228354500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Definition+of+major+bleeding+in+clinical+investigations+of+antihemostatic+medicinal+products+in+non-surgical+patients.&amp;publication_year=2005&amp;journal=J+Thromb+Haemost&amp;pages=692-694&amp;doi=10.1111%2Fj.1538-7836.2005.01204.x&amp;pmid=15842354" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">McGlothlin AE, Viele K. Bayesian hierarchical models. <em>JAMA</em> 2018;320:2365-2366.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.17977" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30535206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452870700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bayesian+hierarchical+models.&amp;publication_year=2018&amp;journal=JAMA&amp;pages=2365-2366&amp;doi=10.1001%2Fjama.2018.17977&amp;pmid=30535206" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the overall estimate (dynamic borrowing). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] receiving ICU-level care at enrollment). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with severe disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. <em>J Am Coll Cardiol</em> 2020;76:1815-1826.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2020.08.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32860872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000579524900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation%2C+bleeding%2C+mortality%2C+and+pathology+in+hospitalized+patients+with+COVID-19.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=1815-1826&amp;doi=10.1016%2Fj.jacc.2020.08.041&amp;pmid=32860872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Ionescu F, Jaiyesimi I, Petrescu I, et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. <em>Eur J Haematol</em> 2021;106:165-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/ejh.13533" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33043484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000585042500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+anticoagulation+dose+and+survival+in+hospitalized+COVID-19+patients%3A+a+retrospective+propensity+score-weighted+analysis.&amp;publication_year=2021&amp;journal=Eur+J+Haematol&amp;pages=165-174&amp;doi=10.1111%2Fejh.13533&amp;pmid=33043484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">FrÃ¶hlich GM, Jeschke E, Eichler U, et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. <em>Clin Res Cardiol</em> 2021;110:1041-1050.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00392-020-01783-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33416918/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000606205900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+oral+anticoagulation+on+clinical+outcomes+of+COVID-19%3A+a+nationwide+cohort+study+of+hospitalized+patients+in+Germany.&amp;publication_year=2021&amp;journal=Clin+Res+Cardiol&amp;pages=1041-1050&amp;doi=10.1007%2Fs00392-020-01783-x&amp;pmid=33416918" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. <em>Blood</em> 2020;135:2033-2040.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020006000" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32339221/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000539154800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=COVID-19+and+its+implications+for+thrombosis+and+anticoagulation.&amp;publication_year=2020&amp;journal=Blood&amp;pages=2033-2040&amp;doi=10.1182%2Fblood.2020006000&amp;pmid=32339221" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. <em>N Engl J Med</em> 2020;383:120-128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMoa2015432&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32437596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571894800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pulmonary+vascular+endothelialitis%2C+thrombosis%2C+and+angiogenesis+in+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=120-128&amp;doi=10.1056%2FNEJMoa2015432&amp;pmid=32437596" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. <em>Lancet Microbe</em> 2020;1(6):e245-e253.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(20)30115-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32844161/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Histopathological+findings+and+viral+tropism+in+UK+patients+with+severe+fatal+COVID-19%3A+a+post-mortem+study.&amp;publication_year=2020&amp;journal=Lancet+Microbe&amp;pages=e245-e253&amp;doi=10.1016%2FS2666-5247%2820%2930115-4&amp;pmid=32844161" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. <em>EClinicalMedicine</em> 2020;24:100434-100434.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eclinm.2020.100434" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32766543/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Megakaryocytes+and+platelet-fibrin+thrombi+characterize+multi-organ+thrombosis+at+autopsy+in+COVID-19%3A+a+case+series.&amp;publication_year=2020&amp;journal=EClinicalMedicine&amp;pages=100434-100434&amp;doi=10.1016%2Fj.eclinm.2020.100434&amp;pmid=32766543" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID-2019. <em>Res Pract Thromb Haemost</em> 2020;4:518-523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rth2.12353" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32542212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000539553300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Using+heparin+molecules+to+manage+COVID-2019.&amp;publication_year=2020&amp;journal=Res+Pract+Thromb+Haemost&amp;pages=518-523&amp;doi=10.1002%2Frth2.12353&amp;pmid=32542212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. <em>JAMA</em> 2021;325:1620-1630.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2021.4152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33734299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000630525600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intermediate-dose+vs+standard-dose+prophylactic+anticoagulation+on+thrombotic+events%2C+extracorporeal+membrane+oxygenation+treatment%2C+or+mortality+among+patients+with+COVID-19+admitted+to+the+intensive+care+unit%3A+the+INSPIRATION+randomized+clinical+trial.&amp;publication_year=2021&amp;journal=JAMA&amp;pages=1620-1630&amp;doi=10.1001%2Fjama.2021.4152&amp;pmid=33734299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Xue M, Zeng Y, Qu H-Q, et al. Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19. <em>ERJ Open Res</em> 2021;7(1):00741-2020-00741-2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/23120541.00741-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33564671/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin-binding+protein+levels+correlate+with+aggravation+and+multiorgan+damage+in+severe+COVID-19.&amp;publication_year=2021&amp;journal=ERJ+Open+Res&amp;pages=00741-2020-00741-2020&amp;doi=10.1183%2F23120541.00741-2020&amp;pmid=33564671" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. <em>J Thromb Thrombolysis</em> 2020;50:287-291.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11239-020-02145-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32445064/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534849000002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin+resistance+in+COVID-19+patients+in+the+intensive+care+unit.&amp;publication_year=2020&amp;journal=J+Thromb+Thrombolysis&amp;pages=287-291&amp;doi=10.1007%2Fs11239-020-02145-0&amp;pmid=32445064" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Fisher J, Linder A. Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis. <em>J Intern Med</em> 2017;281:562-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/joim.12604" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28370601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401715800003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin-binding+protein%3A+a+key+player+in+the+pathophysiology+of+organ+dysfunction+in+sepsis.&amp;publication_year=2017&amp;journal=J+Intern+Med&amp;pages=562-574&amp;doi=10.1111%2Fjoim.12604&amp;pmid=28370601" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">JimÃ©nez D, GarcÃ­a-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. <em>Chest</em> 2021;159:1182-1196.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.chest.2020.11.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33217420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000632456400050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+VTE+and+bleeding+among+hospitalized+patients+with+coronavirus+disease+2019%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2021&amp;journal=Chest&amp;pages=1182-1196&amp;doi=10.1016%2Fj.chest.2020.11.005&amp;pmid=33217420" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/9"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">9</span></span> â¢ <span property="datePublished">August 26, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">790</span>-<span property="pageEnd">802</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: August 4, 2021</div><div><b class="core-label">Published in issue</b>: August 26, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/anticoagulation-thromboembolism-cardiology" alt="View article keyword Anticoagulation/Thromboembolism (Cardiology)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Cardiology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/anticoagulation-thromboembolism-pulmonary-critical-care" alt="View article keyword Anticoagulation/Thromboembolism (Pulmonary/Critical Care)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Pulmonary/Critical Care)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/coronavirus" alt="View article keyword Coronavirus" data-interactiontype="article_recirculation_click">Coronavirus</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person">The ATTACC, ACTIV-4a, and REMAP-CAP Investigators<sup class="xref"><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Peter Munk Cardiac Centre at University Health Network (P.R.L., M.E.F., V.D., J.P.G., L.C.G., G.H.), the University of Toronto (P.R.L., E.C.G., A.S.S., M.E.F., V.D., R.A.F., L.C.G., G.H., M.H.), University Health Network (E.C.G., M.H.), St. Michaelâs Hospital Unity Health (A.S.S., Z.B., J.C.M., M.S.), Ozmosis Research (L.B., L.P.G.D., V.W.), and Sunnybrook Health Sciences Centre (J.P.G.), Toronto, Ottawa Hospital Research Institute (M. Carrier, L.A.C., D.A.F., G.L.G., D.M.S.), Institut du Savoir Montfort (Marc Carrier, G.L.G.), and the University of Ottawa (L.A.C., D.A.F., D.M.S.), Ottawa, UniversitÃ© Laval (A.F.T.) and CHU de QuÃ©becâUniversitÃ© Laval Research Center (A.F.T.), Quebec, QC, the University of Manitoba (B.L.H., A. Kumar, R.Z., S.A.L., D.S., G.V.-G.), CancerCare Manitoba (B.L.H., R.Z.), and St. Boniface Hospital (N.M.), Winnipeg, MB, McGill University, Montreal (S.R.K., E.G.M.), McMaster University (P.L.G.) and the Thrombosis and Atherosclerosis Research Institute (P.L.G.), Hamilton, ON, UniversitÃ© de Sherbrooke, Sherbrooke, QC (F.L.), the University of British Columbia, Vancouver (S. Murthy, K.R.), and the University of Alberta, Edmonton (S.D.) â all in Canada; NYU Grossman School of Medicine (J.S.B., H.R.R., J.S.H., T.C., N.M.K., S.P.), the Icahn School of Medicine at Mount Sinai and Mount Sinai Heart (R.S.R.), NYU Langone Health, NYU Langone Hospital (T.C., J.M.H., E.Y.), and Bellevue Hospital (N.M.K.), New York, Montefiore Medical Center (M.N.G., H.H.B., S.C., J.T.C., R.N.) and Albert Einstein College of Medicine (M.N.G., H.H.B., B.T.G., A. Hope), Bronx, and NYU Langone Long Island, Mineola (R.D.H., A. Hindenburg) â all in New York; the University of Pittsburgh (M.D.N., B.J.M., D.T.H., M.M.B., D.C.A., A.J.K., C.M.L., K.L., S.K.M., C.W.S.), UPMC (M.D.N., B.J.M., D.C.A., K.L., S.K.M.), the Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Center, University of Pittsburgh (T.D.G.), and UPMC Childrenâs Hospital of Pittsburgh (C. Horvat), Pittsburgh, and Emergency Medicine, Penn State Hershey Medical Center, Hershey (S.C.M.) â all in Pennsylvania; Instituto do Coracao, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo (J.C.N., L.C.G., F.G.L.), Avanti Pesquisa ClÃ­nica (A.S.M.), Hospital de Julho (F.O.S.), and Hospital do Coracao (F.G.Z.), Sao Paulo, Hospital do CoraÃ§Ã£o de Mato Grosso do Sul and the Federal University of Mato Grosso do Sul (M.P.), Hospital UniversitÃ¡rio Maria Aparecida Pedrossia (D.G.S.J.), and Hospital Unimed Campo Grande (D.G.S.J.), Campo Grande, and INGOH, Clinical Research Center, GoiÃ¢nia (M.O.S.) â all in Brazil; Instituto Mexicano del Seguro Social, Mexico City (J.E., Y.S.P.G.); the University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust (C.A.B.), Bristol, Imperial College London (A.C.G., F.A.-B., M.A.L.), Imperial College Healthcare NHS Trust, St. Maryâs Hospital (A.C.G.), the London School of Hygiene and Tropical Medicine (B.-A.K.), University College London Hospital (R.H.), Kings Healthcare Partners (B.J.H.), the Intensive Care National Audit and Research Centre (P.R.M.), Guyâs and St. Thomasâ NHS Foundation Trust (M.S.-H.), and Kingâs College London (M.S.-H.), London, Oxford University (A. Beane, S.J.S.) and NHS Blood and Transplant (L.J.E., S.J.S.), Oxford, and Queenâs University Belfast and Royal Victoria Hospital, Belfast (D.F.M.) â all in the United Kingdom; Zuckerberg San Francisco General Hospital, University of California, San Francisco (L.Z.K., C. Hendrickson, M.M.K., A.E.K., M.A.M., B.N.-G.), HarborâUCLA Medical Center, Torrance (R.J.L., S. Brouwer), Global Coalition for Adaptive Research (M. Buxton) and the University of California Los Angeles (G.L.), Los Angeles, the University of California San Diego School of Medicine, San Diego (T.W.C.), and Stanford University School of Medicine, Palo Alto (J.G.W.) â all in California; Larner College of Medicine at the University of Vermont, Burlington (M. Cushman); Australian and New Zealand Intensive Care Research Centre, Monash University (Z.M., A.M.H., C.J.M., S.A.W., A. Buzgau, C.G., S.P.M., A.D.N., J.C.P., A.C.C.), and Alfred Health (A.C.C., A.D.N.), Melbourne, VIC, St. John of God Subiaco Hospital (S.A.W., E. Litton) and Fiona Stanley Hospital (E. Litton), Perth, WA, and Flinders University, Bedford Park, SA (S. Bihari) â all in Australia; the University of Illinois (K.S.K., J.R.J., J.G.Q.), Cook County Health and Rush Medical College (S. Malhotra), and the University of Chicago (J.D.P.) â all in Chicago; SOCAR Research SA, Nyon (B.-A.K.), and Inselspital, Bern University Hospital, University of Bern (T.T.), Bern â all in Switzerland; Berry Consultants, Austin (R.J.L., E. Lorenzi, S.M.B., L.R.B., M.A.D., M.F., A.M., C.T.S.), University of Texas Southwestern Medical Center, Dallas (A.P.), and Baylor Scott and White Health, Temple (R.J.W.) â all in Texas; Auckland City Hospital (C.J.M., S.P.M., R.L.P.) and the University of Auckland (R.L.P.), Auckland, and the Medical Research Institute of New Zealand, Wellington (C.J.M., A.M.T.) â all in New Zealand; Vanderbilt University Medical Center (A.W.A.) and TriStar Centennial Medical Center (A.L.G.) â both in Nashville; FÃ©dÃ©ration Hospitalo Universitaire, Raymond PoincarÃ© Hospital, UniversitÃ© de Versailles Saint-Quentin-en-Yvelines, Garches (D. Annane), and Aix-Marseille University, Marseille (B.C.) â both in France; King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.M.A.); Nepal Mediciti Hospital, Lalitpur, and Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal) â both in Nepal; Versiti Blood Research Institute, Milwaukee (L.B.K., L.J.E.), and the University of Wisconsin School of Medicine and Public Health, Madison (J.P.S.); National Intensive Care SurveillanceâMahidol Oxford Tropical Medicine Research Unit, Colombo, Sri Lanka (A. Beane); the University Medical Center Utrecht, Utrecht University, Utrecht (M. Bonten, R.E.G.S., W.B.-P.), and Radboud University Medical Center, Nijmegen (S. Middeldorp, F.L.V.) â both in the Netherlands; Jena University Hospital, Jena, Germany (F.B.); Cleveland Clinic (A.D.) and Case Western Reserve University, the Metro Health Medical Centre (V.K.) â both in Cleveland; Ochsner Medical Center, University of QueenslandâOchsner Clinical School, New Orleans (M.B.E.); Harvard Medical School (B.M.E., Y.K., N.S.R., A.B.S), Brigham and Womenâs Hospital (B.M.E., Y.K., S.M.H.), Boston University School of Medicine and Boston Medical Center (N.M.H.), and Massachusetts General Hospital (A.B.S., N.S.R.) â all in Boston; University of Alabama, Birmingham (S.G.); Hospital RamÃ³n y Cajal (S.G.-M., J.L.L.-S.M., R.M.G.) and IdiPaz Research Institute, Universidad Autonoma (J.L.-S.), Madrid, and University Hospital of SalamancaâUniversity of Salamanca-IBSAL, Salamanca (M.M.) â all in Spain; University of Antwerp, Wilrijk, Belgium (H.G.); Rutgers New Jersey Medical School, Newark (Y.Y.G.); University of Oxford, Bangkok, Thailand (R.H.); Ascension St. John Heart and Vascular Center, Tulsa (N.H.), and the University of Oklahoma College of Medicine, Oklahoma City (N.H.); the University of Cincinnati, Cincinnati (K.H.); University of Michigan, Ann Arbor (R.C.H., P.K.P.), Beaumont Health, Royal Oak, and the OUWB School of Medicine, Auburn Hills (G.B.N.) â all in Michigan; Mayo Clinic, Rochester (V.N.I.), and the Hennepin County Medical Center, Minneapolis (M.E.P.) â both in Minnesota; Apollo Speciality HospitalâOMR, Chennai, India (D.J.); Oregon Health and Science University, Portland (A. Khan, E.S.L.); the National Heart, Lung, and Blood Institute, Bethesda, MD (A.L.K.); University of Mississippi Medical Center, Jackson (M.E.K.); University College Dublin, Dublin (A.D.N.); University of Kansas School of Medicine, Kansas City (L.S.); Duke University Hospital, Durham, NC (L.W.); and Emory University, Atlanta (B.J.W.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Zarychanski at the Sections of Hematology/Oncology and Critical Care, University of Manitoba, Winnipeg, MB, Canada R3E 0V9, or at <a href="mailto:rzarychanski@cancercare.mb.ca">rzarychanski@cancercare.mb.ca</a>; or to Dr. Hochman at New York University Grossman School of Medicine, New York University Langone Health, 530 First Ave., Skirball 9R, New York, NY, 10016, or at <a href="mailto:judith.hochman@nyumc.org">judith.hochman@nyumc.org</a>.</div><div role="doc-footnote"><div id="fn1" role="paragraph">The members of the writing committee appear at the end of the main text, and the full list of investigators and collaborators appears in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Lawler, Goligher, Berger, Neal, and McVerry and Drs. McArthur, Webb, Farkouh, Hochman, and Zarychanski contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">704</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2105911" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="66811897-db01-a361-dcce-68c2da221905"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995" style="display:inline-block;">
                <img alt="Article has an altmetric score of 1065" src="https://badges.altmetric.com/?size=320&amp;score=1065&amp;types=mbctwfd1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_66811897-db01-a361-dcce-68c2da221905" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=news">
          Picked up by <b>41</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=blogs">
          Blogged by <b>4</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=policy-documents">
          Referenced in <b>2</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=twitter">
          Posted by <b>1190</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=facebook">
          On <b>9</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=wikipedia">
          Referenced in <b>2</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=guidelines">
          Referenced in <b>5</b> clinical guideline sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #70B1FF;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=111143995&amp;tab=bluesky">
          Referenced by <b>1</b> Bluesky users
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>773</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d695b1f5e6f1ff-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2105911"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2105911%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-9%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="704" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">ClÃ©ment R. Massonnaud, </li><li class="list-inline-item cited-by__entry__author">Christof Manuel SchÃ¶nenberger, </li><li class="list-inline-item cited-by__entry__author">Malena Chiaborelli, </li><li class="list-inline-item cited-by__entry__author">Selina Ehrenzeller, </li><li class="list-inline-item cited-by__entry__author">Alexandra Griessbach, </li><li class="list-inline-item cited-by__entry__author">AndrÃ© Gillibert, </li><li class="list-inline-item cited-by__entry__author">Matthias Briel, </li><li class="list-inline-item cited-by__entry__author">CÃ©dric LaouÃ©nan, </li></ul><span class="cited-by__entry__title">Characteristics, design, and statistical methods in platform trials: a systematic review, </span><span class="cited-by__entry__series-title">Journal of Clinical Epidemiology, </span><span class="cited-by__entry__volume"><strong>184</strong>, </span><span class="cited-by__entry__page-range">(111827), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jclinepi.2025.111827" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jclinepi.2025.111827</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jclinepi.2025.111827" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jiameng Yang, </li><li class="list-inline-item cited-by__entry__author">Siyuan Lei, </li><li class="list-inline-item cited-by__entry__author">Yanhong Wei, </li><li class="list-inline-item cited-by__entry__author">Yaoxuan Li, </li><li class="list-inline-item cited-by__entry__author">Rutong Wang, </li><li class="list-inline-item cited-by__entry__author">Haoxuan Xue, </li><li class="list-inline-item cited-by__entry__author">Qiumei Huang, </li><li class="list-inline-item cited-by__entry__author">Kongwei Huang, </li><li class="list-inline-item cited-by__entry__author">Xiaocan Lei, </li></ul><span class="cited-by__entry__title">Bibliometric analysis of advances in polysaccharide pharmacology research: A review, </span><span class="cited-by__entry__series-title">International Journal of Biological Macromolecules, </span><span class="cited-by__entry__volume"><strong>313</strong>, </span><span class="cited-by__entry__page-range">(144159), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ijbiomac.2025.144159" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijbiomac.2025.144159</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijbiomac.2025.144159" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kelechi W Elechi, </li><li class="list-inline-item cited-by__entry__author">Adekunle F Adeoye, </li><li class="list-inline-item cited-by__entry__author">Aliyu O Olaniyi, </li><li class="list-inline-item cited-by__entry__author">Olukunle O Akanbi, </li><li class="list-inline-item cited-by__entry__author">Isaiah Olumeko, </li><li class="list-inline-item cited-by__entry__author">Chukwuma G Udensi, </li><li class="list-inline-item cited-by__entry__author">Toluwanimi J Kolapo, </li><li class="list-inline-item cited-by__entry__author">Vincent U Barrah, </li></ul><span class="cited-by__entry__title">Translational Success and Pharmacoeconomic Lessons of Pandemic-Driven Drug Repurposing, </span><span class="cited-by__entry__series-title">Cureus, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7759/cureus.85033" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7759/cureus.85033</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7759/cureus.85033" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yi Du, </li><li class="list-inline-item cited-by__entry__author">Yang Yang, </li><li class="list-inline-item cited-by__entry__author">Son N. Nguyen, </li><li class="list-inline-item cited-by__entry__author">Igor A. Kaltashov, </li></ul><span class="cited-by__entry__title">The Role of Long-Range Non-Specific Electrostatic Interactions in Inhibiting the Pre-Fusion Proteolytic Processing of the SARS-CoV-2 S Glycoprotein by Heparin, </span><span class="cited-by__entry__series-title">Biomolecules, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(778), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/biom15060778" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/biom15060778</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/biom15060778" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Liwen Xue, </li><li class="list-inline-item cited-by__entry__author">Yuhan Qi, </li><li class="list-inline-item cited-by__entry__author">Yingying Zou, </li></ul><span class="cited-by__entry__title">Short-term safety and efficacy of aspirin in patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials, </span><span class="cited-by__entry__series-title">PeerJ, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__page-range">(e19466), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.7717/peerj.19466" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.7717/peerj.19466</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.7717/peerj.19466" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alexander L Chen, </li><li class="list-inline-item cited-by__entry__author">Matthew Robbins, </li><li class="list-inline-item cited-by__entry__author">Sean Masters, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Boudiab, </li><li class="list-inline-item cited-by__entry__author">Daniel Finn, </li><li class="list-inline-item cited-by__entry__author">Emanuela Peshel, </li><li class="list-inline-item cited-by__entry__author">Gregory Thomas, </li><li class="list-inline-item cited-by__entry__author">Diane Studzinski, </li><li class="list-inline-item cited-by__entry__author">Steven Truscott, </li><li class="list-inline-item cited-by__entry__author">Courtney Watterworth, </li><li class="list-inline-item cited-by__entry__author">Nathan Novotny, </li><li class="list-inline-item cited-by__entry__author">Felicia Ivascu, </li><li class="list-inline-item cited-by__entry__author">Anthony Iacco, </li></ul><span class="cited-by__entry__title">Examining the role of thromboelastography in patients with COVID-19, </span><span class="cited-by__entry__series-title">Perfusion, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1177/02676591251340967" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1177/02676591251340967</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1177/02676591251340967" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maryam Aleissa, </li><li class="list-inline-item cited-by__entry__author">Ernesto Drelichman, </li><li class="list-inline-item cited-by__entry__author">Jasneet Bhullar, </li></ul><span class="cited-by__entry__title">Ischemic Colitis and Small Bowel Ischemia in a Vaccinated Patient with Mild COVID-19 Infection: A Case Report, </span><span class="cited-by__entry__series-title">Case Reports in Gastroenterology, </span><span class="cited-by__entry__volume"><strong>19</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(335-339), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1159/000545495" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1159/000545495</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1159/000545495" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Haiming Hu, </li><li class="list-inline-item cited-by__entry__author">Yixing Zhu, </li><li class="list-inline-item cited-by__entry__author">Ruikang Hu, </li><li class="list-inline-item cited-by__entry__author">Lijuan Zhao, </li><li class="list-inline-item cited-by__entry__author">Xiangwen Zeng, </li><li class="list-inline-item cited-by__entry__author">Xue Wu, </li><li class="list-inline-item cited-by__entry__author">Rui Qiu, </li><li class="list-inline-item cited-by__entry__author">Yihao Nie, </li><li class="list-inline-item cited-by__entry__author">Lokesh Sharma, </li><li class="list-inline-item cited-by__entry__author">De Chang, </li></ul><span class="cited-by__entry__title">Prophylactic anticoagulant therapy is associated with improved survival in ICU patients with non-COVID-19 pneumonia: a retrospective cohort study, </span><span class="cited-by__entry__series-title">Frontiers in Pharmacology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fphar.2025.1597885" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fphar.2025.1597885</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fphar.2025.1597885" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Antonios M. Diab, </li><li class="list-inline-item cited-by__entry__author">Hailey M. Stack, </li><li class="list-inline-item cited-by__entry__author">Brendan T. McKeown, </li><li class="list-inline-item cited-by__entry__author">Bruce C. Carleton, </li><li class="list-inline-item cited-by__entry__author">Kerry B. Goralski, </li></ul><span class="cited-by__entry__title">Systematic review of Health Canada approved clinical therapeutic trials for the treatment or prevention of coronavirus disease 2019 (COVID-19), </span><span class="cited-by__entry__series-title">Canadian Journal of Physiology and Pharmacology, </span><span class="cited-by__entry__volume"><strong>103</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(146-162), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1139/cjpp-2024-0055" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1139/cjpp-2024-0055</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1139/cjpp-2024-0055" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nicholas Heming, </li><li class="list-inline-item cited-by__entry__author">Lindsay Berry, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Lorenzi, </li><li class="list-inline-item cited-by__entry__author">Thomas E. Hills, </li><li class="list-inline-item cited-by__entry__author">Alisa M. Higgins, </li><li class="list-inline-item cited-by__entry__author">Yaseen Arabi, </li><li class="list-inline-item cited-by__entry__author">Diptesh Aryal, </li><li class="list-inline-item cited-by__entry__author">Abigail Beane, </li><li class="list-inline-item cited-by__entry__author">Janis Best-Lane, </li><li class="list-inline-item cited-by__entry__author">Marc Bonten, </li><li class="list-inline-item cited-by__entry__author">Charlotte Bradbury, </li><li class="list-inline-item cited-by__entry__author">Frank Brunkhorst, </li><li class="list-inline-item cited-by__entry__author">Aidan Burrell, </li><li class="list-inline-item cited-by__entry__author">Meredith Buxton, </li><li class="list-inline-item cited-by__entry__author">Maurizio Cecconi, </li><li class="list-inline-item cited-by__entry__author">James D. Chalmers, </li><li class="list-inline-item cited-by__entry__author">Allen C. Cheng, </li><li class="list-inline-item cited-by__entry__author">Graham Cooke, </li><li class="list-inline-item cited-by__entry__author">Matthew E. Cove, </li><li class="list-inline-item cited-by__entry__author">Paul Dark, </li><li class="list-inline-item cited-by__entry__author">Lennie Derde, </li><li class="list-inline-item cited-by__entry__author">Michelle A. Detry, </li><li class="list-inline-item cited-by__entry__author">Lise J. Estcourt, </li><li class="list-inline-item cited-by__entry__author">Mark Fitzgerald, </li><li class="list-inline-item cited-by__entry__author">Anthony C. Gordon, </li><li class="list-inline-item cited-by__entry__author">Cameron Green, </li><li class="list-inline-item cited-by__entry__author">Rashan Haniffa, </li><li class="list-inline-item cited-by__entry__author">Madiha Hashmi, </li><li class="list-inline-item cited-by__entry__author">Leanne Hays, </li><li class="list-inline-item cited-by__entry__author">Christopher Horvat, </li><li class="list-inline-item cited-by__entry__author">David T. Huang, </li><li class="list-inline-item cited-by__entry__author">Nao Ichihara, </li><li class="list-inline-item cited-by__entry__author">Devachandran Jayakumar, </li><li class="list-inline-item cited-by__entry__author">Peter S. Kruger, </li><li class="list-inline-item cited-by__entry__author">Francois Lamontagne, </li><li class="list-inline-item cited-by__entry__author">Patrick R. Lawler, </li><li class="list-inline-item cited-by__entry__author">Roger J. Lewis, </li><li class="list-inline-item cited-by__entry__author">Edward Litton, </li><li class="list-inline-item cited-by__entry__author">John C. Marshall, </li><li class="list-inline-item cited-by__entry__author">Colin J. McArthur, </li><li class="list-inline-item cited-by__entry__author">Daniel F. McAuley, </li><li class="list-inline-item cited-by__entry__author">Anna McGlothlin, </li><li class="list-inline-item cited-by__entry__author">Shay McGuinness, </li><li class="list-inline-item cited-by__entry__author">Zoe McQuilten, </li><li class="list-inline-item cited-by__entry__author">Bryan J. McVerry, </li><li class="list-inline-item cited-by__entry__author">Susan C. Morpeth, </li><li class="list-inline-item cited-by__entry__author">Paul R. Mouncey, </li><li class="list-inline-item cited-by__entry__author">Alistair D. Nichol, </li><li class="list-inline-item cited-by__entry__author">Rachael L. Parke, </li><li class="list-inline-item cited-by__entry__author">Jane C. Parker, </li><li class="list-inline-item cited-by__entry__author">Svenja Peters, </li><li class="list-inline-item cited-by__entry__author">Padmanabhan Ramnarayan, </li><li class="list-inline-item cited-by__entry__author">Luis Felipe Reyes, </li><li class="list-inline-item cited-by__entry__author">Kathryn M. Rowan, </li><li class="list-inline-item cited-by__entry__author">Hiroki Saito, </li><li class="list-inline-item cited-by__entry__author">Marlene S. Santos, </li><li class="list-inline-item cited-by__entry__author">Christina T. Saunders, </li><li class="list-inline-item cited-by__entry__author">Christopher Seymour, </li><li class="list-inline-item cited-by__entry__author">Manu Shankar-Hari, </li><li class="list-inline-item cited-by__entry__author">Vanessa Singh, </li><li class="list-inline-item cited-by__entry__author">Paul A. Tambyah, </li><li class="list-inline-item cited-by__entry__author">Alexis F. Turgeon, </li><li class="list-inline-item cited-by__entry__author">Anne M. Turner, </li><li class="list-inline-item cited-by__entry__author">Andrew Ustianowski, </li><li class="list-inline-item cited-by__entry__author">Frank L. van de Veerdonk, </li><li class="list-inline-item cited-by__entry__author">Alicia A. C. Waite, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Whittaker, </li><li class="list-inline-item cited-by__entry__author">Ryan Zarychanski, </li><li class="list-inline-item cited-by__entry__author">Srinivas Murthy, </li><li class="list-inline-item cited-by__entry__author">Steven A. Webb, </li><li class="list-inline-item cited-by__entry__author">Scott Berry, </li><li class="list-inline-item cited-by__entry__author">Balasubramanian Venkatesh, </li><li class="list-inline-item cited-by__entry__author">Djillali Annane, </li><li class="list-inline-item cited-by__entry__author">Derek C. Angus, </li></ul><span class="cited-by__entry__title">Effect of hydrocortisone on mortality in patients with severe community-acquired pneumonia, </span><span class="cited-by__entry__series-title">Intensive Care Medicine, </span><span class="cited-by__entry__volume"><strong>51</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(665-680), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s00134-025-07861-w" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00134-025-07861-w</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00134-025-07861-w" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2105911%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-9%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105911" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2105911" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2105911.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f0.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/d477dd93-5bc5-43ef-aef8-5832aad30af4/assets/images/large/nejmoa2105911_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f1.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/8e88a364-6d92-45a5-b6ec-234dbad89aa5/assets/images/large/nejmoa2105911_f1.jpg" height="2788" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Enrollment, and Randomization, According to Trial Group.</div><div class="notes"><div role="doc-footnote">Trial sites used varying screening and documentation practices during the coronavirus disease 2019 (Covid-19) pandemic to identify eligible patients, as described in the protocol. Of the 13,373 patients who underwent screening, 7202 were assessed for eligibility in the ATTACC platform, 3799 in the ACTIV-4a platform, and 2372 in the REMAP-CAP platform. Under reasons for exclusion from the trial, âotherâ includes not meeting an inclusion criterion (including a lack of diagnosis of Covid-19), an anticipated duration of hospital stay of less than 72 hours, or meeting an exclusion criterion that is not specified here. Data for patients who had severe disease at baseline could be used for covariate adjustment and dynamic borrowing calculations in the primary analysis. The numbers of patients who were randomly assigned to the treatment groups were imbalanced owing to the use of response-adaptive randomization.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f2.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/7cea410f-d2eb-4f0d-9deb-f6321921de30/assets/images/large/nejmoa2105911_f2.jpg" height="2421" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Days without Organ Support among All the Patients with Moderate Disease.</div><div class="notes"><div role="doc-footnote">Panel A shows the distribution of organ supportâfree days among all the patients with moderate disease. The ordinal scale includes a score of â1 (in-hospital death, the worst possible outcome), a score of 0 to 21 (the numbers of days alive without organ support), and a score of 22 (survival until hospital discharge without receipt of organ support, the best possible outcome). The difference in the height of the two curves at any point represents the difference in the cumulative probability of having a value for days without organ support of less than or equal to that point on the x axis. Panel B shows the number of days without organ support as horizontally stacked proportions of patients in the two treatment groups, with the following possible outcomes: in-hospital death with or without the receipt of organ support (dark red, the worst possible outcome, corresponding to a score of â1 on the ordinal scale); survival with organ support provided in an intensive care unit (ICU) (red-to-blue gradient shading based on the number of days alive without organ support; intermediate outcome, corresponding to a score of 0 to 21 on the ordinal scale); and survival until hospital discharge without ICU-level organ support (dark blue, the best possible outcome, corresponding to a score of 22 on the ordinal scale).</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2105911/asset/70fa6fc0-4f64-4278-9edb-5faf015fba38/assets/images/large/nejmoa2105911_t1.jpg" height="3438" width="1586" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Therapeutic-Dose<br>Anticoagulation<br>(N=1181)</th><th class="txxr-borders">Usual-Care<br>Thromboprophylaxis<br>(N=1050)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Age Â±SD â yr</td><td class="xxxx-borders shading">59.0Â±14.1</td><td class="xxxr-borders shading">58.8Â±13.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex â no. (%)</td><td class="xxxx-borders">713 (60.4)</td><td class="xxxr-borders">597 (56.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race or ethnic group â no./total no. (%)<a href="#core-t1fn2" role="doc-noteref">â </a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">622/994 (62.6)</td><td class="xxxr-borders">564/845 (66.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">41/994 (4.1)</td><td class="xxxr-borders shading">43/845 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">219/994 (22.0)</td><td class="xxxr-borders">162/845 (19.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">First Nations or American Indian</td><td class="xxxx-borders shading">118/965 (12.2)</td><td class="xxxr-borders shading">82/819 (10.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">17/1109 (1.5)</td><td class="xxxr-borders">16/968 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hispanic or Latino</td><td class="xxxx-borders shading">574/1004 (57.2)</td><td class="xxxr-borders shading">537/879 (61.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median body-mass index (IQR)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders">29.8 (26.3â34.7)</td><td class="xxxr-borders">30.3 (26.7â34.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Preexisting condition â no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hypertension</td><td class="xxxx-borders">546/1023 (53.4)</td><td class="xxxr-borders">447/892 (50.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Diabetes mellitus</td><td class="xxxx-borders shading">352/1181 (29.8)</td><td class="xxxr-borders shading">311/1049 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Severe cardiovascular disease<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">123/1165 (10.6)</td><td class="xxxr-borders">121/1038 (11.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Chronic kidney disease</td><td class="xxxx-borders shading">83/1173 (7.1)</td><td class="xxxr-borders shading">69/1037 (6.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Chronic respiratory disease<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders">249/1132 (22.0)</td><td class="xxxr-borders">212/988 (21.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Immunosuppressive disease</td><td class="xxxx-borders shading">105/1143 (9.2)</td><td class="xxxr-borders shading">103/1005 (10.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Treatment â no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Antiplatelet agent<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">148/1140 (13.0)</td><td class="xxxr-borders shading">111/1013 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Remdesivir</td><td class="xxxx-borders">428/1178 (36.3)</td><td class="xxxr-borders">383/1048 (36.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Glucocorticoid</td><td class="xxxx-borders shading">479/791 (60.6)</td><td class="xxxr-borders shading">415/656 (63.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Tocilizumab</td><td class="xxxx-borders">6/1178 (0.5)</td><td class="xxxr-borders">7/1048 (0.7)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Respiratory support â no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">None</td><td class="xxxx-borders">156 (13.2)</td><td class="xxxr-borders">123 (11.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low-flow nasal cannula or face mask</td><td class="xxxx-borders shading">789 (66.8)</td><td class="xxxr-borders shading">696 (66.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High-flow nasal cannula</td><td class="xxxx-borders">25 (2.1)</td><td class="xxxr-borders">28 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Noninvasive mechanical ventilation</td><td class="xxxx-borders shading">21 (1.8)</td><td class="xxxr-borders shading">24 (2.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Unspecified<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">190 (16.1)</td><td class="xxxr-borders">179 (17.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Median laboratory value (IQR)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median <span data-style="small-caps">d</span>-dimer level relative to ULN at trial site</td><td class="xxxx-borders">1.6 (0.9â2.6)</td><td class="xxxr-borders">1.5 (1.0â2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Platelets â per mm<sup>3</sup></td><td class="xxxx-borders shading">221,000 (171,000â290,000)</td><td class="xxxr-borders shading">218,000 (172,500â289,000)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Lymphocytes â per mm<sup>3</sup></td><td class="xxxx-borders">900 (700â1300)</td><td class="xxxr-borders">1000 (700â1400)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Creatinine â mg/dl</td><td class="xxxx-borders shading">0.9 (0.7â1.1)</td><td class="xxxr-borders shading">0.9 (0.7â1.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Platform of enrollment â no. (%)<a href="#core-t1fn8" role="doc-noteref">â â </a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">ATTACC<a href="#core-t1fn9" role="doc-noteref">â¡â¡</a></td><td class="xxxx-borders shading">650 (55.0)</td><td class="xxxr-borders shading">509 (48.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">ACTIV-4a</td><td class="xxxx-borders">387 (32.8)</td><td class="xxxr-borders">392 (37.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">REMAP-CAP</td><td class="xxxx-borders shading">144 (12.2)</td><td class="xxxr-borders shading">149 (14.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Country of enrollment â no./total no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">United Kingdom</td><td class="xxxx-borders shading">95/1181 (8.0)</td><td class="xxxr-borders shading">103/1050 (9.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">United States</td><td class="xxxx-borders">573/1181 (48.5)</td><td class="xxxr-borders">507/1050 (48.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Canada</td><td class="xxxx-borders shading">102/1181 (8.6)</td><td class="xxxr-borders shading">83/1050 (7.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Brazil</td><td class="xxxx-borders">234/1181 (19.8)</td><td class="xxxr-borders">209/1050 (19.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Other<a href="#core-t1fn10" role="doc-noteref">Â§Â§</a></td><td class="xbxx-borders shading">177/1181 (15.0)</td><td class="xbxr-borders shading">148/1050 (14.1)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"><div class="label">*</div></a><div id="core-t1fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg">Listed are data that were included in the analysis involving patients with moderate severity of coronavirus disease 2019 (Covid-19). The denominators of patients in the anticoagulation group and the thrombophylaxis group are unequal owing to response-adaptive randomization. The baseline characteristics of the patients according to <span data-style="small-caps">d</span>-dimer level are provided in Table S2 in the </a><a href="#ap2">Supplementary Appendix</a>. To convert the values for creatinine to micromoles per liter, multiply by 88.4. ULN denotes upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race or ethnic group was reported by the patients.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Severe cardiovascular disease was defined as a baseline history of heart failure, myocardial infarction, coronary artery disease, peripheral arterial disease, or cerebrovascular disease (stroke or transient ischemic attack) in the ATTACC (Antithrombotic Therapy to Ameliorate Complications of Covid-19) and ACTIV-4a (A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19) platforms and as a baseline history of New York Heart Association class IV symptoms in the REMAP-CAP platform (Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia).</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Chronic respiratory disease was defined as a baseline history of asthma, chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, primary lung cancer, pulmonary hypertension, active tuberculosis, or the receipt of home oxygen therapy.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Not listed are 74 patients who were coenrolled in the REMAP-CAP Antiplatelet Domain (39 in the anticoagulation group and 35 in the thromboprophylaxis group).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">In REMAP-CAP, levels of oxygen support (including no support) below the level of high-flow nasal cannula were not reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">The relative proportion of patients who were randomly assigned in each platform was imbalanced owing to implementation of response-adaptive randomization in ATTACC on December 15, 2020.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡â¡</div><div id="core-t1fn9" role="paragraph" data-to-manipulate="true">A total of 215 patients who were enrolled in the ATTACC platform were funded by the ACTIV4a platform by the National Heart, Lung, and Blood Institute.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§Â§</div><div id="core-t1fn10" role="paragraph" data-to-manipulate="true">Other participating countries were Mexico, Nepal, Australia, the Netherlands, and Spain.</div></div></div></figcaption><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2105911/asset/36eaacfe-d91c-4a1f-adf0-a041ba9f14ed/assets/images/large/nejmoa2105911_t2.jpg" height="1654" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders">Therapeutic-Dose Anticoagulation</th><th class="txxx-borders">Usual-Care Thrombo-prophylaxis</th><th class="txxx-borders">Adjusted Difference in Risk<br>(95% Credible Interval)<a href="#core-t2fn2" role="doc-noteref">â </a></th><th class="txxx-borders">Adjusted<br>Odds Ratio<br>(95% Credible Interval)<a href="#core-t2fn3" role="doc-noteref">â¡</a></th><th class="txxr-borders">Probability of Superiority of Therapeutic-Dose Anticoagulation</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>no. of patients/total no. (%)</span></th><th class="xxxx-borders">percentage points</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Patients with moderate disease</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Overall group<a href="#core-t2fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders">939/1171 (80.2)</td><td class="xxxx-borders">801/1048 (76.4)</td><td class="xxxx-borders">4.0<br>(0.5 to 7.2)</td><td class="xxxx-borders">1.27<br>(1.03â1.58)</td><td class="xxxr-borders">98.6</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><span data-style="small-caps">d</span>-dimer cohort<a href="#core-t2fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">High level</td><td class="xxxx-borders">264/339 (77.9)</td><td class="xxxx-borders">210/291 (72.2)</td><td class="xxxx-borders">5.1<br>(0.0 to 9.9)</td><td class="xxxx-borders">1.31<br>(1.00â1.76)</td><td class="xxxr-borders">97.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Low level</td><td class="xxxx-borders shading">463/570 (81.2)</td><td class="xxxx-borders shading">403/505 (79.8)</td><td class="xxxx-borders shading">3.0<br>(â1.2 to 6.3)</td><td class="xxxx-borders shading">1.22<br>(0.93â1.57)</td><td class="xxxr-borders shading">92.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Unknown level</td><td class="xbxx-borders">212/262 (80.9)</td><td class="xbxx-borders">188/252 (74.6)</td><td class="xbxx-borders">4.9<br>(0.00 to 9.9)</td><td class="xbxx-borders">1.32<br>(1.00â1.86)</td><td class="xbxr-borders">97.3</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The primary outcome was organ supportâfree days, evaluated on an ordinal scale that combined in-hospital death and the number of days free of cardiovascular or respiratory organ support up to day 21 among patients who survived to hospital discharge. Because the majority of patients in the two treatment groups survived until hospital discharge without receipt of critical careâlevel organ support, the median value for organ supportâfree days was 22 in both groups. Accordingly, the proportion of patients in each treatment group who survived until hospital discharge without receipt of organ support (22 on the ordinal scale) is reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The adjusted difference in risk is based on the event frequency in the usual-care thromboprophylaxis group and the odds ratio after adjustment for age, sex, site, <span data-style="small-caps">d</span>-dimer group, and enrollment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The odds ratio is for the therapeutic-dose anticoagulation group as compared with the usual-care thromboprophylaxis group. The odds ratios are adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period, which may be imbalanced due to the use of response-adaptive randomization.</div></div></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><div class="label">Â§</div></a><div id="core-t2fn4" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg">This model assumes a single treatment effect in all the patients with moderate disease regardless of the baseline <span data-style="small-caps">d</span>-dimer level. Dynamic borrowing of information on the treatment effect from patients who had severe illness at baseline was permitted, in which similar treatment effects were grouped together on the basis of their degree of similarity. Results from a sensitivity analysis assuming independent treatment effects between disease-severity cohorts are provided in Table S5 in the </a><a href="#ap2">Supplementary Appendix</a>.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">The primary adaptive model estimated treatment effects with the use of a Bayesian hierarchical approach in the following groups: patients with severe disease and those with moderate disease stratified according to their baseline high <span data-style="small-caps">d</span>-dimer level (â¥2 times the ULN, low <span data-style="small-caps">d</span>-dimer level (&lt;2 times the ULN), or unknown <span data-style="small-caps">d</span>-dimer level. This model permitted dynamic borrowing across illness-severity and <span data-style="small-caps">d</span>-dimer cohorts, in which similar treatment effects are grouped together on the basis of their degree of similarity. Accordingly, observations about treatment effect are shared between groups. Results from a sensitivity analysis assuming independent treatment effects among <span data-style="small-caps">d</span>-dimerâdefined cohorts are also provided in Table S5.</div></div></div></figcaption><figcaption><div class="caption">Primary Outcome of Organ SupportâFree Days.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2105911/asset/0e9277d1-2b21-4a0f-b0be-26136f1eec7a/assets/images/large/nejmoa2105911_t3.jpg" height="1562" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders">Therapeutic-Dose Anticoagulation</th><th class="txxx-borders">Usual-Care <br>Thromboprophylaxis</th><th class="txxx-borders">Adjusted<br>Difference in Risk<br>(95% Credible Interval)<a href="#core-t3fn2" role="doc-noteref">â </a></th><th class="txxx-borders">Adjusted<br>Odds Ratio<br>(95% Credible Interval)<a href="#core-t3fn3" role="doc-noteref">â¡</a></th><th class="txxr-borders">Probability of Effect of Therapeutic-Dose Anticoagulation</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>no. of patients/total no. (%)</span></th><th class="xxxx-borders">percentage points</th><td class="xxxx-borders">&nbsp;</td><th class="xxxr-borders">%</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Survival until hospital discharge</td><td class="xxxx-borders shading">1085/1171 (92.7)</td><td class="xxxx-borders shading">962/1048 (91.8)</td><td class="xxxx-borders shading">1.3<br>(â1.1 to 3.2)</td><td class="xxxx-borders shading">1.21<br>(0.87 to 1.68)<a href="#core-t3fn4" role="doc-noteref">Â§</a></td><td class="xxxr-borders shading">87.1<a href="#core-t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Survival without organ support at 28 days<a href="#core-t3fn6" role="doc-noteref">â</a></td><td class="xxxx-borders">932/1175 (79.3)</td><td class="xxxx-borders">789/1046 (75.4)</td><td class="xxxx-borders">4.5<br>(0.9 to 7.7)</td><td class="xxxx-borders">1.30<br>(1.05 to 1.61)</td><td class="xxxr-borders">99.1<a href="#core-t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Progression to intubation or death<a href="#core-t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">129/1181 (10.9)</td><td class="xxxx-borders shading">127/1050 (12.1)</td><td class="xxxx-borders shading">â1.9<br>(â4.1 to 0.7)</td><td class="xxxx-borders shading">0.82<br>(0.63 to 1.07)</td><td class="xxxr-borders shading">92.2<a href="#core-t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Major thrombotic event or death</td><td class="xxxx-borders">94/1180 (8.0)</td><td class="xxxx-borders">104/1046 (9.9)</td><td class="xxxx-borders">â2.6<br>(â4.4 to â0.2)</td><td class="xxxx-borders">0.72<br>(0.53 to 0.98)</td><td class="xxxr-borders">98.0<a href="#core-t3fn5" role="doc-noteref">Â¶</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Major thrombotic event</td><td class="xxxx-borders shading">13/1180 (1.1)</td><td class="xxxx-borders shading">22/1046 (2.1)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Death in hospital</td><td class="xxxx-borders">86/1180 (7.3)</td><td class="xxxx-borders">86/1046 (8.2)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Major bleeding</td><td class="xbxx-borders shading">22/1180 (1.9)</td><td class="xbxx-borders shading">9/1047 (0.9)</td><td class="xbxx-borders shading">0.7<br>(â0.1 to 2.3)</td><td class="xbxx-borders shading">1.80<br>(0.90 to 3.74)</td><td class="xbxr-borders shading">95.5<a href="#core-t3fn8" role="doc-noteref">â â </a></td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Secondary end points were modeled without dynamic borrowing. In these analyses, a single treatment effect was assumed regardless of the <span data-style="small-caps">d</span>-dimer level. Additional secondary end points, including those categorized according to the <span data-style="small-caps">d</span>-dimer cohort, are provided in Table S6.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The adjusted difference in risk is based on the event rate in the usual-care thromboprophylaxis group and the odds ratio after adjustment for age, sex, site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">The odds ratio is for the therapeutic-dose anticoagulation group as compared with the usual-care thromboprophylaxis group. The odds ratios are adjusted for age, sex, trial site, <span data-style="small-caps">d</span>-dimer cohort, and enrollment period, which may be imbalanced due to the use of response-adaptive randomization.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">In a model that included borrowing of information on treatment effect from patients with severe disease, the median adjusted odds ratio for survival until hospital discharge was 1.18 (95% credible interval, 0.86 to 1.63), with a posterior probability of superiority of 84.4%.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">In this category, the probability of superiority is shown.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">Survival without organ support at 28 days was modeled as a dichotomous outcome. Similar results were obtained after the exclusion of 52 patients who were receiving organ support at baseline (median adjusted odds ratio, 1.30; 95% credible interval, 1.06 to 1.62), with a posterior probability of superiority of 99.3%.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">Progression to intubation or death was modeled as an ordinal outcome with death as the worst possible outcome.</div></div><div role="doc-footnote" data-has="label"><div class="label">â â </div><div id="core-t3fn8" role="paragraph" data-to-manipulate="true">For major bleeding, the probability of inferiority is shown.</div></div></div></figcaption></a><figcaption><div class="caption">Secondary Outcomes among All Patients with Moderate Disease.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2105911_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2105911</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. <em>Lancet</em> 2020;395:1054-1062.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)30566-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32171076/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522650100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+course+and+risk+factors+for+mortality+of+adult+inpatients+with+COVID-19+in+Wuhan%2C+China%3A+a+retrospective+cohort+study.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1054-1062&amp;doi=10.1016%2FS0140-6736%2820%2930566-3&amp;pmid=32171076" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Mody A, Lyons PG, Vazquez Guillamet C, et al. The clinical course of coronavirus disease 2019 in a US hospital system: a multistate analysis. <em>Am J Epidemiol</em> 2021;190:539-552.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/aje/kwaa286" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33351077/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000644497600007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+clinical+course+of+coronavirus+disease+2019+in+a+US+hospital+system%3A+a+multistate+analysis.&amp;publication_year=2021&amp;journal=Am+J+Epidemiol&amp;pages=539-552&amp;doi=10.1093%2Faje%2Fkwaa286&amp;pmid=33351077" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. <em>JAMA</em> 2020;323:2052-2059.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.6775" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32320003/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538023900036" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Presenting+characteristics%2C+comorbidities%2C+and+outcomes+among+5700+patients+hospitalized+with+COVID-19+in+the+New+York+City+area.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=2052-2059&amp;doi=10.1001%2Fjama.2020.6775&amp;pmid=32320003" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. <em>BMJ</em> 2020;369:m1923-m1923.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmj.m1923" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32444358/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000538336800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence%2C+clinical+outcomes%2C+and+transmission+dynamics+of+severe+coronavirus+disease+2019+in+California+and+Washington%3A+prospective+cohort+study.&amp;publication_year=2020&amp;journal=BMJ&amp;pages=m1923-m1923&amp;doi=10.1136%2Fbmj.m1923&amp;pmid=32444358" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Garibaldi BT, Fiksel J, Muschelli J, et al. Patient trajectories among persons hospitalized for COVID-19: a cohort study. <em>Ann Intern Med</em> 2021;174:33-41.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.7326/M20-3905" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32960645/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000619485200019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patient+trajectories+among+persons+hospitalized+for+COVID-19%3A+a+cohort+study.&amp;publication_year=2021&amp;journal=Ann+Intern+Med&amp;pages=33-41&amp;doi=10.7326%2FM20-3905&amp;pmid=32960645" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. <em>JAMA</em> 2020;324:799-801.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2020.13372" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32702090/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000568230000033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Thrombosis+in+hospitalized+patients+with+COVID-19+in+a+New+York+City+health+system.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=799-801&amp;doi=10.1001%2Fjama.2020.13372&amp;pmid=32702090" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] associated with a poor clinical outcome. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] thrombosis and a poor clinical outcome. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. <em>CMAJ</em> 2020;192(40):E1156-E1161.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1503/cmaj.201240" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32816822/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000581747900003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticipating+and+managing+coagulopathy+and+thrombotic+manifestations+of+severe+COVID-19.&amp;publication_year=2020&amp;journal=CMAJ&amp;pages=E1156-E1161&amp;doi=10.1503%2Fcmaj.201240&amp;pmid=32816822" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Clausen TM, Sandoval DR, Spliid CB, et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. <em>Cell</em> 2020;183(4):1043.e15-1057.e15.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cell.2020.09.033" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32970989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000588640900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2+infection+depends+on+cellular+heparan+sulfate+and+ACE2.&amp;publication_year=2020&amp;journal=Cell&amp;pages=1043.e15-1057.e15&amp;doi=10.1016%2Fj.cell.2020.09.033&amp;pmid=32970989" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J. Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. <em>EBioMedicine</em> 2020;59:102969-102969.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ebiom.2020.102969" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32853989/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000575450100008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Beneficial+non-anticoagulant+mechanisms+underlying+heparin+treatment+of+COVID-19+patients.&amp;publication_year=2020&amp;journal=EBioMedicine&amp;pages=102969-102969&amp;doi=10.1016%2Fj.ebiom.2020.102969&amp;pmid=32853989" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Mycroft-West CJ, Su D, Pagani I, et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. <em>Thromb Haemost</em> 2020;120:1700-1715.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0040-1721319" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33368089/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000601223000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin+inhibits+cellular+invasion+by+SARS-CoV-2%3A+structural+dependence+of+the+interaction+of+the+spike+S1+receptor-binding+domain+with+heparin.&amp;publication_year=2020&amp;journal=Thromb+Haemost&amp;pages=1700-1715&amp;doi=10.1055%2Fs-0040-1721319&amp;pmid=33368089" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] possibly antiviral properties of heparins, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] and potentially antiviral mechanisms. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Chowdhury JF, Moores LK, Connors JM. Anticoagulation in hospitalized patients with Covid-19. <em>N Engl J Med</em> 2020;383:1675-1678.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_12_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMclde2028217&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33085867/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582579100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation+in+hospitalized+patients+with+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=1675-1678&amp;doi=10.1056%2FNEJMclde2028217&amp;pmid=33085867" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Short SAP, Gupta S, Brenner SK, et al. d-Dimer and death in critically ill patients with coronavirus disease 2019. <em>Crit Care Med</em> 2021;49(5):e500-e511.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/CCM.0000000000004917" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33591017/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000640883100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=d-Dimer+and+death+in+critically+ill+patients+with+coronavirus+disease+2019.&amp;publication_year=2021&amp;journal=Crit+Care+Med&amp;pages=e500-e511&amp;doi=10.1097%2FCCM.0000000000004917&amp;pmid=33591017" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. <em>Crit Care</em> 2020;24:559-559.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13054-020-03273-y" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32938471/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000574593700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+published+guidelines+for+management+of+coagulopathy+and+thrombosis+in+critically+ill+patients+with+COVID+19%3A+implications+for+clinical+practice+and+future+investigations.&amp;publication_year=2020&amp;journal=Crit+Care&amp;pages=559-559&amp;doi=10.1186%2Fs13054-020-03273-y&amp;pmid=32938471" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Rosovsky RP, Sanfilippo KM, Wang TF, et al. Anticoagulation practice patterns in COVID-19: a global survey. <em>Res Pract Thromb Haemost</em> 2020;4:969-983.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rth2.12414" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32838111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562909000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation+practice+patterns+in+COVID-19%3A+a+global+survey.&amp;publication_year=2020&amp;journal=Res+Pract+Thromb+Haemost&amp;pages=969-983&amp;doi=10.1002%2Frth2.12414&amp;pmid=32838111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Houston BL, Lawler PR, Goligher EC, et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): study design and methodology for an international, adaptive Bayesian randomized controlled trial. <em>Clin Trials</em> 2020;17:491-500.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/1740774520943846" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32815416/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000561686100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anti-Thrombotic+Therapy+to+Ameliorate+Complications+of+COVID-19+%28ATTACC%29%3A+study+design+and+methodology+for+an+international%2C+adaptive+Bayesian+randomized+controlled+trial.&amp;publication_year=2020&amp;journal=Clin+Trials&amp;pages=491-500&amp;doi=10.1177%2F1740774520943846&amp;pmid=32815416" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and Design. <em>Ann Am Thorac Soc</em> 2020;17:879-891.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1513/AnnalsATS.202003-192SD" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32267771/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000546620500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+REMAP-CAP+%28Randomized+Embedded+Multifactorial+Adaptive+Platform+for+Community-acquired+Pneumonia%29+study.+Rationale+and+Design.&amp;publication_year=2020&amp;journal=Ann+Am+Thorac+Soc&amp;pages=879-891&amp;doi=10.1513%2FAnnalsATS.202003-192SD&amp;pmid=32267771" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. <em>N Engl J Med</em> 2021;385:777-789.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMoa2103417&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34351722/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000683387200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Therapeutic+anticoagulation+with+heparin+in+critically+ill+patients+with+Covid-19&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=777-789&amp;doi=10.1056%2FNEJMoa2103417&amp;pmid=34351722" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r17-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] severe Covid-19 are reported separately. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] December 19, 2020, as reported separately. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Schulman S, Kearon C, the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <em>J Thromb Haemost</em> 2005;3:692-694.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2005.01204.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15842354/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000228354500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Definition+of+major+bleeding+in+clinical+investigations+of+antihemostatic+medicinal+products+in+non-surgical+patients.&amp;publication_year=2005&amp;journal=J+Thromb+Haemost&amp;pages=692-694&amp;doi=10.1111%2Fj.1538-7836.2005.01204.x&amp;pmid=15842354" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">McGlothlin AE, Viele K. Bayesian hierarchical models. <em>JAMA</em> 2018;320:2365-2366.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.17977" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30535206/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000452870700020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Bayesian+hierarchical+models.&amp;publication_year=2018&amp;journal=JAMA&amp;pages=2365-2366&amp;doi=10.1001%2Fjama.2018.17977&amp;pmid=30535206" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the overall estimate (dynamic borrowing). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] receiving ICU-level care at enrollment). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with severe disease. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. <em>J Am Coll Cardiol</em> 2020;76:1815-1826.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2020.08.041" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32860872/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000579524900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Anticoagulation%2C+bleeding%2C+mortality%2C+and+pathology+in+hospitalized+patients+with+COVID-19.&amp;publication_year=2020&amp;journal=J+Am+Coll+Cardiol&amp;pages=1815-1826&amp;doi=10.1016%2Fj.jacc.2020.08.041&amp;pmid=32860872" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Ionescu F, Jaiyesimi I, Petrescu I, et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. <em>Eur J Haematol</em> 2021;106:165-174.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/ejh.13533" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33043484/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000585042500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+anticoagulation+dose+and+survival+in+hospitalized+COVID-19+patients%3A+a+retrospective+propensity+score-weighted+analysis.&amp;publication_year=2021&amp;journal=Eur+J+Haematol&amp;pages=165-174&amp;doi=10.1111%2Fejh.13533&amp;pmid=33043484" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">FrÃ¶hlich GM, Jeschke E, Eichler U, et al. Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany. <em>Clin Res Cardiol</em> 2021;110:1041-1050.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s00392-020-01783-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33416918/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000606205900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+oral+anticoagulation+on+clinical+outcomes+of+COVID-19%3A+a+nationwide+cohort+study+of+hospitalized+patients+in+Germany.&amp;publication_year=2021&amp;journal=Clin+Res+Cardiol&amp;pages=1041-1050&amp;doi=10.1007%2Fs00392-020-01783-x&amp;pmid=33416918" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. <em>Blood</em> 2020;135:2033-2040.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood.2020006000" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32339221/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000539154800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=COVID-19+and+its+implications+for+thrombosis+and+anticoagulation.&amp;publication_year=2020&amp;journal=Blood&amp;pages=2033-2040&amp;doi=10.1182%2Fblood.2020006000&amp;pmid=32339221" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. <em>N Engl J Med</em> 2020;383:120-128.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_25_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2105911&amp;key=10.1056%2FNEJMoa2015432&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32437596/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571894800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pulmonary+vascular+endothelialitis%2C+thrombosis%2C+and+angiogenesis+in+Covid-19.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=120-128&amp;doi=10.1056%2FNEJMoa2015432&amp;pmid=32437596" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. <em>Lancet Microbe</em> 2020;1(6):e245-e253.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2666-5247(20)30115-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32844161/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Histopathological+findings+and+viral+tropism+in+UK+patients+with+severe+fatal+COVID-19%3A+a+post-mortem+study.&amp;publication_year=2020&amp;journal=Lancet+Microbe&amp;pages=e245-e253&amp;doi=10.1016%2FS2666-5247%2820%2930115-4&amp;pmid=32844161" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. <em>EClinicalMedicine</em> 2020;24:100434-100434.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.eclinm.2020.100434" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32766543/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Megakaryocytes+and+platelet-fibrin+thrombi+characterize+multi-organ+thrombosis+at+autopsy+in+COVID-19%3A+a+case+series.&amp;publication_year=2020&amp;journal=EClinicalMedicine&amp;pages=100434-100434&amp;doi=10.1016%2Fj.eclinm.2020.100434&amp;pmid=32766543" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Liu J, Li J, Arnold K, Pawlinski R, Key NS. Using heparin molecules to manage COVID-2019. <em>Res Pract Thromb Haemost</em> 2020;4:518-523.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rth2.12353" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32542212/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000539553300001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Using+heparin+molecules+to+manage+COVID-2019.&amp;publication_year=2020&amp;journal=Res+Pract+Thromb+Haemost&amp;pages=518-523&amp;doi=10.1002%2Frth2.12353&amp;pmid=32542212" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. <em>JAMA</em> 2021;325:1620-1630.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2021.4152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33734299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000630525600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+intermediate-dose+vs+standard-dose+prophylactic+anticoagulation+on+thrombotic+events%2C+extracorporeal+membrane+oxygenation+treatment%2C+or+mortality+among+patients+with+COVID-19+admitted+to+the+intensive+care+unit%3A+the+INSPIRATION+randomized+clinical+trial.&amp;publication_year=2021&amp;journal=JAMA&amp;pages=1620-1630&amp;doi=10.1001%2Fjama.2021.4152&amp;pmid=33734299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Xue M, Zeng Y, Qu H-Q, et al. Heparin-binding protein levels correlate with aggravation and multiorgan damage in severe COVID-19. <em>ERJ Open Res</em> 2021;7(1):00741-2020-00741-2020.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/23120541.00741-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33564671/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin-binding+protein+levels+correlate+with+aggravation+and+multiorgan+damage+in+severe+COVID-19.&amp;publication_year=2021&amp;journal=ERJ+Open+Res&amp;pages=00741-2020-00741-2020&amp;doi=10.1183%2F23120541.00741-2020&amp;pmid=33564671" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">White D, MacDonald S, Bull T, et al. Heparin resistance in COVID-19 patients in the intensive care unit. <em>J Thromb Thrombolysis</em> 2020;50:287-291.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s11239-020-02145-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32445064/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534849000002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin+resistance+in+COVID-19+patients+in+the+intensive+care+unit.&amp;publication_year=2020&amp;journal=J+Thromb+Thrombolysis&amp;pages=287-291&amp;doi=10.1007%2Fs11239-020-02145-0&amp;pmid=32445064" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Fisher J, Linder A. Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis. <em>J Intern Med</em> 2017;281:562-574.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/joim.12604" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28370601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000401715800003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Heparin-binding+protein%3A+a+key+player+in+the+pathophysiology+of+organ+dysfunction+in+sepsis.&amp;publication_year=2017&amp;journal=J+Intern+Med&amp;pages=562-574&amp;doi=10.1111%2Fjoim.12604&amp;pmid=28370601" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">JimÃ©nez D, GarcÃ­a-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. <em>Chest</em> 2021;159:1182-1196.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.chest.2020.11.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33217420/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000632456400050" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Incidence+of+VTE+and+bleeding+among+hospitalized+patients+with+coronavirus+disease+2019%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2021&amp;journal=Chest&amp;pages=1182-1196&amp;doi=10.1016%2Fj.chest.2020.11.005&amp;pmid=33217420" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Nov 17, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2115560" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Therapeutic Anticoagulation with Heparin in Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 04, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2103417" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">The REMAP-CAP, ACTIV-4a, and ATTACC Investigators</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 04, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2111151" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Surviving Covid-19 with Heparin?</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">H. ten Cate</span></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Clifton, New Jersey</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890427/faculty-gastroenterologist-outpatient-department-of-gastroenterology-hackensack-univ-med-center/?query=fjwp&amp;rid=121829">Faculty Gastroenterologist - Outpatient, Department of Gastroenterology, Hackensack Univ Med Center</a></div></div><div class="nejm-widget_item"><div><span> Somerville, Massachusetts</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888841/obstetrics-gynecology-physician/?query=fjwp&amp;rid=1038">Obstetrics/Gynecology - Physician</a></div></div><div class="nejm-widget_item"><div><span> San Antonio, Texas</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890312/endocrinologist-multidisciplinary-system-lots-of-support/?query=fjwf&amp;rid=346908">Endocrinologist - multidisciplinary system, lots of support</a></div></div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Otolaryngology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891183/otolaryngology-head-and-neck-surgery-assistant-professor-columbiadoctors-westchester/?query=fjwf&amp;rid=108014">Otolaryngology Head &amp; Neck Surgery, Assistant Professor, ColumbiaDoctors, Westchester</a></div></div><div class="nejm-widget_item"><div><span> Pittsburgh, Pennsylvania</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890270/family-medicine-physician-30000-00-sign-on/?query=fjwf&amp;rid=346908">Family Medicine Physician -$30000.00 sign on</a></div></div><div class="nejm-widget_item"><div><span> Bridgeport, Connecticut</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893604/per-diem-hospitalist/?query=fjwf&amp;rid=36610">Per Diem Hospitalist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2105911&amp;pubId=41290603&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d695b1f5e6f1ff-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d695b1f5e6f1ff-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d695b1f5e6f1ff-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$797701228$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$797701228$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$797701228$--></div></div><div class="mlt-body"><!--?lit$797701228$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$797701228$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$797701228$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$797701228$-->Mar 31, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2118691?query=recirc_Semantic" target="_self">Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection</a></div><div class="mlt-article-authors"><!--?lit$797701228$-->V. Hall and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$797701228$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$797701228$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$797701228$-->Nov 18, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2107934?query=recirc_Semantic" target="_self">Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab</a></div><div class="mlt-article-authors"><!--?lit$797701228$-->A. Gupta and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$797701228$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$797701228$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$797701228$-->Feb 22, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2400160?query=recirc_Semantic" target="_self">More on PreâCovid-19, SARS-CoV-2âNegative MIS-C</a></div><div class="mlt-article-authors"><!--?lit$797701228$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$797701228$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$797701228$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$797701228$-->Jan 21, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2029849?query=recirc_Semantic" target="_self">SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19</a></div><div class="mlt-article-authors"><!--?lit$797701228$-->P. Chen and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$797701228$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$797701228$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$797701228$-->Nov 30, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2307574?query=recirc_Semantic" target="_self">PreâCovid-19, SARS-CoV-2âNegative Multisystem Inflammatory Syndrome in Children</a></div><div class="mlt-article-authors"><!--?lit$797701228$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2105911?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2105911" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2105911.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2105911"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2103417" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2034031" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>A Monoclonal Antibody for Malaria Prevention</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f0.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/d477dd93-5bc5-43ef-aef8-5832aad30af4/assets/images/large/nejmoa2105911_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f1.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/8e88a364-6d92-45a5-b6ec-234dbad89aa5/assets/images/large/nejmoa2105911_f1.jpg" height="2788" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Enrollment, and Randomization, According to Trial Group.</div><div class="notes"><div role="doc-footnote">Trial sites used varying screening and documentation practices during the coronavirus disease 2019 (Covid-19) pandemic to identify eligible patients, as described in the protocol. Of the 13,373 patients who underwent screening, 7202 were assessed for eligibility in the ATTACC platform, 3799 in the ACTIV-4a platform, and 2372 in the REMAP-CAP platform. Under reasons for exclusion from the trial, âotherâ includes not meeting an inclusion criterion (including a lack of diagnosis of Covid-19), an anticipated duration of hospital stay of less than 72 hours, or meeting an exclusion criterion that is not specified here. Data for patients who had severe disease at baseline could be used for covariate adjustment and dynamic borrowing calculations in the primary analysis. The numbers of patients who were randomly assigned to the treatment groups were imbalanced owing to the use of response-adaptive randomization.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2105911_f2.jpg"><img src="/cms/10.1056/NEJMoa2105911/asset/7cea410f-d2eb-4f0d-9deb-f6321921de30/assets/images/large/nejmoa2105911_f2.jpg" height="2421" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Days without Organ Support among All the Patients with Moderate Disease.</div><div class="notes"><div role="doc-footnote">Panel A shows the distribution of organ supportâfree days among all the patients with moderate disease. The ordinal scale includes a score of â1 (in-hospital death, the worst possible outcome), a score of 0 to 21 (the numbers of days alive without organ support), and a score of 22 (survival until hospital discharge without receipt of organ support, the best possible outcome). The difference in the height of the two curves at any point represents the difference in the cumulative probability of having a value for days without organ support of less than or equal to that point on the x axis. Panel B shows the number of days without organ support as horizontally stacked proportions of patients in the two treatment groups, with the following possible outcomes: in-hospital death with or without the receipt of organ support (dark red, the worst possible outcome, corresponding to a score of â1 on the ordinal scale); survival with organ support provided in an intensive care unit (ICU) (red-to-blue gradient shading based on the number of days alive without organ support; intermediate outcome, corresponding to a score of 0 to 21 on the ordinal scale); and survival until hospital discharge without ICU-level organ support (dark blue, the best possible outcome, corresponding to a score of 22 on the ordinal scale).</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Primary Outcome of Organ SupportâFree Days.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Secondary Outcomes among All Patients with Moderate Disease.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/9" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 9</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 26, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2100665" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Triple Therapy for Cystic Fibrosis <em>Phe508del</em>âGating and âResidual Function Genotypes</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P.J. Barry and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 26, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2034031" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Monoclonal Antibody for Malaria Prevention</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M.R. Gaudinski and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 26, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra2104091" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Heparin Resistance â Clinical Perspectives and Management Strategies</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.H. Levy and J.M. Connors</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2105911%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2105911&amp;pubId=41290603&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2105911%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2105911&amp;pubId=41290603&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06151129265799753" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d695b1f5e6f1ff-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d695b1f5e6f1ff-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d695b1f5e6f1ff-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d695b1f5e6f1ff-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d695b1f5e6f1ff-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d695b1f5e6f1ff-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d695b1f5e6f1ff-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d695b1f5e6f1ff-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d695b1f5e6f1ff-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d695b1f5e6f1ff-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d695b1ee40f1ff',t:'MTc0OTUzNDU1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d695b1ee40f1ff&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><cmq-ndbekrehsegf></cmq-ndbekrehsegf><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2105911?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-transactionid="07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" id="captureIFrame_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" target="captureIFrame_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="capture_screen"><input id="capture_signIn_js_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="js_version"><input id="capture_signIn_transactionId_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" type="hidden" class="capture_transactionId_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="capture_transactionId"><input id="capture_signIn_form_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="form"><input id="capture_signIn_flow_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="flow"><input id="capture_signIn_client_id_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="client_id"><input id="capture_signIn_redirect_uri_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="redirect_uri"><input id="capture_signIn_response_type_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="response_type"><input id="capture_signIn_flow_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="flow_version"><input id="capture_signIn_settings_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="settings_version"><input id="capture_signIn_locale_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="locale"><input id="capture_signIn_recaptcha_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_07lyihq65wotzm5q1ast0i1tqps945zn0pgzibjv" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>